Office of Directorate General of Foreign Trade
New Delhi -0

Para 4.07 Decision

Minutes of the Norms Committee – 3 Meeting No. 6/82-ALC4/2020 dated 13.11.2020 (actually held on 18.11.2020 and 25.11.2020) for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2015-20 pertaining to Chemical and Allied products falling under Chapter 29 and 30, held under the Chairmanship of Shri Rajbir Sharma, Jt. DGFT in Room No.4 and 11, Udyog Bhawan, New Delhi.

Following members were present in the Meeting:

Sl. No.	Name & Designation	Department
1	Shri Shaish Kumar, Technical – 1	Consultant
2	Shri D.N. Mathur, Technical – 2	Consultant
In attendance		
1	Shri Munish Kumar, Dy. DGFT	DGFT
2	Shri Ajay Kumar, Assistant Director	DGFT

2. The Norms Committee has taken decision only with respect to technical aspect/ wastage norms. While redeeming the application, RAs should check that the applicant has fulfilled all requirements as prescribed in policy/procedure including those in policy circulars issued from time to time or any other provisions under FTP/HBP for issuance of Advance Authorization and regularization of the case.

The committee went through the minutes of earlier meeting No. 5/82-ALC4/2020 dated 09.10.2020 (actually held on 26.10.2020 and 09.11.2020)

ONLINE CASES

Case No.:40/6/82-ALC4/2020	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
HQ File :01/82/050/01649/AM21/	RLA File :09/24/040/00563/AM15/	Lic.No/Date:0910061513 08.01.2015	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

Case No.:93/20/82-ALC4/2015	Party Name:INTAS PHARMACEUTICALS LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01676/AM16/	RLA File :08/24/040/00329/AM16/	Lic.No/Date:0810136966 06.01.2016	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	AZITHROMYCIN TABLETS 250 MG EACH FILM COATED TABLET CONTAINS: AZITHROMYCIN MONOHYDRATE EQUIVALENT TO AZITHROMYCIN 250 MG [AVERAGE WATER CONTENT NLT 5%] --- 268.42 MG/TABLET	1 Number	1	AZITHROMYCIN MONOHYDRATE EP / BP / USP / IP / PH.EUR.	261.809 mg / 250 mg Tablet
2	AZITHROMYCIN TABLETS 500 MG EACH FILM COATED TABLET CONTAINS: AZITHROMYCIN MONOHYDRATE EQUIVALENT TO AZITHROMYCIN 500 MG [AVERAGE WATER CONTENT NLT 5%] --- 536.84 MG/TABLET [IN WHICH ACTIVE INGREDIENT AZITHROMYCIN MONOHYDRATE USED IS 300.000 KGS]	1 Number	1	AZITHROMYCIN MONOHYDRATE EP / BP / USP / IP / PH.EUR.	522.26 mg / 500 mg Tablet

RA concerned may take further necessary action as per above decision of NC.

Case No.:6/11/85-ALC3/2016	Party Name:GELTEC PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Transferred to Different Section**
3 HQ File :01/85/050/00103/AM17/	RLA File :03/94/040/00502/AM17/	Lic.No/Date:0310807611 06.09.2016	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was observed that the ITC HS Code of Export Product starts with 21, which pertains to NC-VI.

In view of above, the Committee decided to **transfer the case to NC-VI**.

4	**Case No.:28/6/82-ALC4/2020**	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01637/AM21/	RLA File :03/95/040/00192/AM18/	Lic.No/Date:0310814209 22.06.2017	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10%(Available Iodine NLT 1% w/v) (Net content of Povidone Iodine - 6862.740(KGS)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

5	**Case No.:33/6/82-ALC4/2020**	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01642/AM21/	RLA File :03/95/040/00544/AM18/	Lic.No/Date:0310816499 25.10.2017	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10%(Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

6	**Case No.:39/6/82-ALC4/2020**	Party Name:MEDREICH LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01648/AM21/	RLA File :07/24/040/00192/AM18/	Lic.No/Date:0710112322 27.10.2017	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE

7	**Case No.:43/6/82-ALC4/2020**	Party Name:ENVEE DRUGS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01652/AM21/	RLA File :34/24/040/00218/AM18/	Lic.No/Date:3410043680 06.12.2017	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019 against advance authorization No. 0310831597 dated 17.09.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
CLOBETASOL PROPIONATE BP/USP	1 kg	1	BETAMETHASONE IP/BP/USP/EP	1.00 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

8	**Case No.:35/6/82-ALC4/2020**	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01644/AM21/	RLA File :03/95/040/00797/AM18/	Lic.No/Date:0310818035 27.12.2017	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10%(Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

9	**Case No.:37/6/82-ALC4/2020**	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01646/AM21/	RLA File :03/95/040/01061/AM18/	Lic.No/Date:0310819689 09.03.2018	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10% (Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

	Case No.:29/6/82-ALC4/2020	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01638/AM21/	RLA File :03/95/040/00221/AM19/	Lic.No/Date:0310821782 20.06.2018	

10 **Decision:** The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10%(Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

	Case No.:31/6/82-ALC4/2020	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01640/AM21/	RLA File :03/95/040/00306/AM19/	Lic.No/Date:0310822067 02.07.2018	

11 **Decision:** The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10%(Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

	Case No.:32/6/82-ALC4/2020	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01641/AM21/	RLA File :03/95/040/00409/AM19/	Lic.No/Date:0310822769 01.08.2018	

12 **Decision:** The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10% (Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

13	**Case No.:34/6/82-ALC4/2020**	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01643/AM21/	RLA File :03/95/040/00672/AM19/	Lic.No/Date:0310824350 10.10.2018	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10% (Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

14	**Case No.:36/6/82-ALC4/2020**	Party Name:SIRMAXO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01645/AM21/	RLA File :03/95/040/00847/AM19/	Lic.No/Date:0310825266 28.11.2018	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 against advance authorization No. 0310807807 dated 15.09.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Povidone Iodine Topical Solution USP 10% (Available Iodine NLT 1% w/v)	1 kg	1	Povidone Iodine	0.098 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

15	**Case No.:136/6/82-ALC4/2019**	Party Name:ENCUBE ETHICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00362/AM20/	RLA File :03/94/040/01057/AM19/	Lic.No/Date:0310827548 08.03.2019	

Decision: Deferred for comments of TE.

16	**Case No.:12/1/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00012/AM20/	RLA File :09/24/040/00661/AM19/	Lic.No/Date:0910067365 04.04.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
(3S)-OXOLAN-3-AMINE HYDROGEN CHLORIDE	1 kg	1	D (+) - MALIC ACID	2.05 kg

RA concerned may take further necessary action as per above decision of NC.

17	**Case No.:42/1/82-ALC4/2019**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00042/AM20/	RLA File :05/23/040/00015/AM20/	Lic.No/Date:0510410233 15.04.2019	

Decision: The Committee considered the case as per agenda and it was observed that the firm was issued Show Cause Notice vide letter dated 10.10.2019.

18	**Case No.:43/1/82-ALC4/2019**	Party Name:HEMA DYE CHEM PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00043/AM20/	RLA File :03/94/040/01141/AM19/	Lic.No/Date:0310828400 16.04.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
1,3 DIMETHOXY BENZENE/RESORCINOL DIMETHYL ETHER/M-DIMETHOXYBEZENE	1 kg	1	RESORCINOL/1,3DIHYDROXYBENZENE	0.8778 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.:66/1/82-ALC4/2019	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00066/AM20/	RLA File :09/24/040/00013/AM20/	Lic.No/Date:0910067405 24.04.2019	

19 **Decision:** The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
3-FLUORO-4-NITROPHENOL	1 kg	1	3-FLUORO PHENOL	1.427 kg
		2	METHYL TERTIARY BUTYL ETHER	2.28 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.:67/1/82-ALC4/2019	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
HQ File :01/82/050/00067/AM20/	RLA File :09/24/040/00025/AM20/	Lic.No/Date:0910067414 24.04.2019	

20 **Decision:** The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm:

(i) Standard composition of Export Item.
(ii) Copy of relevant DML.
(iii) COA of Export Item.

Case No.:75/1/82-ALC4/2019	Party Name:LABORATE PHARMACEUTICAL INDIA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00075/AM20/	RLA File :33/24/040/00003/AM20/	Lic.No/Date:3310030529 24.04.2019	

21 **Decision:** The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 2/82-ALC4/2020 dated 10.07.2020 against advance authorization No. 3310030519 dated 14.03.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Clindamycin Phosphate Cream /Gel 30gm 1% w/w (Clindamycin Phosphate 0.41gm is equivalent to 30 gm Clindamycin)	1 Number Tube of 30 gms	1	Clindamycin Phosphate IP/BP/USP A raw material in powder form	364.14 mg

RA concerned may take further necessary action as per above decision of Norms Committee.

22	**Case No.:86/1/82-ALC4/2019**	Party Name:ASCENT FINECHEM PVT. LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00086/AM20/	RLA File :08/24/040/00005/AM20/	Lic.No/Date:0810145144 01.05.2019	
	Decision: Deferred for comments of TE.			

23	**Case No.:101/1/82-ALC4/2019**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00101/AM20/	RLA File :05/23/040/00048/AM20/	Lic.No/Date:0510410475 03.05.2019	
	Decision: The Committee considered the case as per agenda and it was observed that the firm was issued Show Cause Notice vide letter dated 10.10.2019.			

24	**Case No.:106/1/82-ALC4/2019**	Party Name:PRACHEM LABORATORIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00106/AM20/	RLA File :08/24/040/00003/AM20/	Lic.No/Date:0810145205 08.05.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.11.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, the case is deferred.			

25	**Case No.:107/1/82-ALC4/2019**	Party Name:SHANKUS PHARMACEUTICALS	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Withdrawn**
	HQ File :01/82/050/00107/AM20/	RLA File :08/24/040/00040/AM20/	Lic.No/Date:0810145203 08.05.2019	
	Decision: The firm vide e-mail dated 07.10.2020 has informed that they have submitted the subject Advance Authorization in RLA Ahmedabad for cancellation. In view of above, the Committee decided to **withdraw** the case. RA concerned may verify the same and take further necessary action as per policy / procedures.			

26	**Case No.:113/1/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00113/AM20/	RLA File :09/24/040/00011/AM20/	Lic.No/Date:0910067466 09.05.2019	
	Decision: Deferred for comments of TE.			

27	**Case No.:109/1/82-ALC4/2019**	Party Name:SAURAV CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00109/AM20/	RLA File :22/24/040/00011/AM20/	Lic.No/Date:2210016146 10.05.2019	
	Decision: Deferred for comments of TE.			

28	**Case No.:251/1/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00157/AM20/	RLA File :09/24/040/00043/AM20/	Lic.No/Date:0910067519 14.05.2019	
	Decision: Deferred for comments of TE.			

29	**Case No.:276/1/82-ALC4/2019**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00182/AM20/	RLA File :03/95/040/00143/AM20/	Lic.No/Date:0310829108 17.05.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 25.02.2020 has furnished its reply. Deferred for comments of TE.			

30	**Case No.:280/1/82-ALC4/2019**	Party Name:SMS LIFESCIENCES INDIA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00186/AM20/	RLA File :09/24/040/00084/AM20/	Lic.No/Date:0910067561 22.05.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
EZETIMIBE (ETZ-IV) INTERMEDIATE	1 kg	1	(S)-4-PHENYL-OXAZOLIDIN-2-ONE	0.45 kg
		2	IMMCALA-T2-150 (ENZYME)	0.066 kg
		3	METHYLENE DICHLORIDE	6.00 kg
		4	METHANOL	4.40 kg
		5	N-HEPTANE	3.20 kg
		6	TOLUENE	7.80 kg
		7	POTASSIUM HYDROXIDE FLAKES	0.90 kg
		8	ISO PROPYL ALCOHOL	3.00 kg
		9	DI METHYL FORMAMIDE	0.40 kg

RA concerned may take further necessary action as per above decision of NC.

31	**Case No.:299/1/82-ALC4/2019**	Party Name:RUBICON RESEARCH PVT. LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00205/AM20/	RLA File :03/95/040/00103/AM20/	Lic.No/Date:0310829246 24.05.2019	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2020 dated 07.08.2020 against advance authorization No. 0310830404 dated 18.07.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Cyclobenzaprine Tablet 5 MG (Net content of Super Tab 3990 kg)	1 Number	1	Anhydrous Lactose USP (Super Tab 21 AN)	95.00 mg / 5 mg tablet
2	Cyclobenzaprine Tablet 10 mg (Net content of Super Tab 12015 kg)	1 Number	1	Anhydrous Lactose USP (Super Tab 21 AN)	90.00 mg / 10 mg tablet

RA concerned may take further necessary action as per above decision of Norms Committee.

32	**Case No.:301/1/82-ALC4/2019**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00207/AM20/	RLA File :03/94/040/00134/AM20/	Lic.No/Date:0310829265 27.05.2019	

Decision: Deferred for comments of TE.

33	**Case No.:305/1/82-ALC4/2019**	Party Name:RUMIT CHEMISYNTH PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00211/AM20/	RLA File :03/95/040/00196/AM20/	Lic.No/Date:0310829292 28.05.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm:

(i) Complete chemistry, molecular weight, % yield, material balance and stoichiometric balance.

34	**Case No.:319/1/82-ALC4/2019**	Party Name:RAVESHIA ORGANICS LLP	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00225/AM20/	RLA File :03/95/040/00204/AM20/	Lic.No/Date:0310829355 30.05.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 10.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Application is still awaited. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

35	**Case No.:1/6/82-ALC4/2019**	Party Name:MALLADI DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00227/AM20/	RLA File :04/24/040/00048/AM20/	Lic.No/Date:0410165665 31.05.2019	
	Decision: Deferred for comments of TE.			

36	**Case No.:18/6/82-ALC4/2019**	Party Name:SMILAX LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00244/AM20/	RLA File :09/24/040/00103/AM20/	Lic.No/Date:0910067628 06.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2, 2-dimethyl-1, 3-dioxan-4-yl)acetate	1 kg	1	(4R,6R)-Tert-Butyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate (ATS-8)	0.588kg

RA concerned may take further necessary action as per above decision of NC.

37	**Case No.:30/6/82-ALC4/2019**	Party Name:TIDE INDUSTRIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00256/AM20/	RLA File :34/24/040/00083/AM20/	Lic.No/Date:3410045200 10.06.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Justification for very low yield of 45.78%.** **(ii) Commercial value of low boiler and high boiler.** **(iii) Production / Consumption data duly certified by GST for last one year.**			

38	**Case No.:36/6/82-ALC4/2019**	Party Name:NOVEL NUTRIENTS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00262/AM20/	RLA File :07/24/040/00056/AM20/	Lic.No/Date:0710115041 11.06.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: **(i) Copy of Approval from Food & Drugs Administration (FDA) for the export product.** **(ii) COA for import item from foreign supplier.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

39	**Case No.:33/6/82-ALC4/2019**	Party Name:ASHISH LIFE SCIENCE PVT.LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00259/AM20/	RLA File :03/94/040/00197/AM20/	Lic.No/Date:0310829569 12.06.2019	
	Decision: Deferred for comments of TE.			

40	**Case No.:34/6/82-ALC4/2019**	Party Name:DIPS BIOSCIENCE PVT.LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00260/AM20/	RLA File :03/94/040/00199/AM20/	Lic.No/Date:0310829573 12.06.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: **(i) Copy of DML for each export product item showing Approved composition** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

41	**Case No.:45/6/82-ALC4/2019**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00271/AM20/	RLA File :09/24/040/00114/AM20/	Lic.No/Date:0910067664 13.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
VELPATASVIR-COPOVIDONE (1:1)	1 kg	1	Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4,3:6,7]naphtha[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl)carbamate	0.555 kg

RA concerned may take further necessary action as per above decision of NC.

42	**Case No.:49/6/82-ALC4/2019**	Party Name:DHANUKA LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00275/AM20/	RLA File :05/23/040/00104/AM20/	Lic.No/Date:0510410949 14.06.2019	

Decision: Deferred for comments of TE.

43	**Case No.:50/6/82-ALC4/2019**	Party Name:VISION DRUGS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00276/AM20/	RLA File :09/24/040/00121/AM20/	Lic.No/Date:0910067669 14.06.2019	

Decision: Deferred for comments of TE.

44	**Case No.:53/6/82-ALC4/2019**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00279/AM20/	RLA File :03/94/040/00201/AM20/	Lic.No/Date:0310829703 17.06.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Manufacturing process in detail.** **(ii) Wastage at each stage of manufacturing.**			

45	**Case No.:60/6/82-ALC4/2019**	Party Name:TIDE INDUSTRIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00286/AM20/	RLA File :34/24/040/00101/AM20/	Lic.No/Date:3410045217 18.06.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Exact chemical name of Export Product.**			

46	**Case No.:61/6/82-ALC4/2019**	Party Name:ASTRAL STERITECH PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00287/AM20/	RLA File :34/24/040/00102/AM20/	Lic.No/Date:3410045218 19.06.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2 019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

47	**Case No.:67/6/82-ALC4/2019**	Party Name:ASTRAL STERITECH PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00293/AM20/	RLA File :34/24/040/00100/AM20/	Lic.No/Date:3410045222 20.06.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

48	**Case No.:75/6/82-ALC4/2019**	Party Name:NAARI PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00301/AM20/	RLA File :05/24/040/00172/AM20/	Lic.No/Date:0510411026 24.06.2019	
	Decision: Deferred for comments of TE.			

49	**Case No.:76/6/82-ALC4/2019**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00302/AM20/	RLA File :09/24/040/00132/AM20/	Lic.No/Date:0910067687 24.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl.No.	Import items	Qty.
[2S,3S,5S]-5-t-butyloxycarbonylamino-2-Amino-3-hydroxy-1,6-diphenylhexane succinate(BDH Succinic Acid RIT)	1 kg	1	1,2-dimethoxy ethane(1,2-DME)	4.74 kg
		2	SODIUM BORO HYDRIDE	0.45 kg
		3	METHANE SULPHONIC ACID	1.50 kg
		4	L-Phenylalanine	Not shown in the process

RA concerned may take further necessary action as per above decision of NC.

50	**Case No.:77/6/82-ALC4/2019**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00303/AM20/	RLA File :09/24/040/00133/AM20/	Lic.No/Date:0910067688 24.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl.No.	Import items	Qty.
2S,3S,5S)-2-AMINO-3-HYDROXY-5-(1-TETRA-HYDRO PYRIMID-2-ONLY)-3-METHYL BUTANOYL) AMINO-1,6-DIPHENYL HEXANE-S-PYRO GLUTAMATE(THP)	1 kg	1	L-PHENYLALANINE	0.473 kg
		2	1,2 DIMETHOXYETHANE	6.74 kg
		3	SODIUM BORO HYDRIDE	0.406 kg
		4	METHANE SULPHONIC ACID	1.57 kg
		5	L- VALINE	0.63 kg
		6	N,N- CARBONYL DIMIDAZOLE	0.443 kg
		7	L-PYROGLUTAMIC ACID	0.295 kg

RA concerned may take further necessary action as per above decision of NC.

51	**Case No.:93/6/82-ALC4/2019**	Party Name:CONCORD BIOTECH LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00319/AM20/	RLA File :08/24/040/00101/AM20/	Lic.No/Date:0810145581 27.06.2019	
	Decision: Deferred for comments of TE.			

52	**Case No.:30/6/82-ALC4/2020**	Party Name:NOCIL LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01639/AM21/	RLA File :03/95/040/00284/AM20/	Lic.No/Date:0310829992 28.06.2019	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE			

53	**Case No.:103/6/82-ALC4/2019**	Party Name:SMILAX LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00329/AM20/	RLA File :09/24/040/00146/AM20/	Lic.No/Date:0910067735 02.07.2019	
	Decision: Deferred for comments of TE.			

54	**Case No.:114/6/82-ALC4/2019**	Party Name:TITAN LABORATORIES PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00340/AM20/	RLA File :03/95/040/00318/AM20/	Lic.No/Date:0310830043 03.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 07.10.2020 has furnished its reply. Deferred for comments of TE.			

55	**Case No.:117/6/82-ALC4/2019**	Party Name:SYNTHO CHIRALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00343/AM20/	RLA File :09/24/040/00172/AM20/	Lic.No/Date:0910067749 03.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

56	**Case No.:122/6/82-ALC4/2019**	Party Name:PROLIFE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00348/AM20/	RLA File :03/95/040/00329/AM20/	Lic.No/Date:0310830123 05.07.2019	
	Decision: Deferred for comments of TE.			

57	**Case No.:127/6/82-ALC4/2019**	Party Name:APNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00353/AM20/	RLA File :34/24/040/00098/AM20/	Lic.No/Date:3410045258 05.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder on 11.06.2020 and Final Reminder on 06.10.2020: **(i) Export quantity to be given in number of Tablets / Capsules.** **(ii) Detailed working of inputs applied.** **(iii) Master Batch Formula for each export product.** Hence, the case is deferred.			

58	**Case No.:130/6/82-ALC4/2019**	Party Name:ACME GENERICS LLP	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00356/AM20/	RLA File :22/24/040/00026/AM20/	Lic.No/Date:2210016194 08.07.2019	
	Decision: Deferred for comments of TE.			

59	**Case No.:145/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00371/AM20/	RLA File :08/24/040/00114/AM20/	Lic.No/Date:0810145666 09.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 30.10.2020 has furnished its reply. Deferred for comments of TE.			

60	**Case No.:150/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00376/AM20/	RLA File :08/24/040/00116/AM20/	Lic.No/Date:0810145668 09.07.2019	
	Decision: Deferred for comments of TE.			

61	**Case No.:151/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00377/AM20/	RLA File :08/24/040/00117/AM20/	Lic.No/Date:0810145669 09.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 30.10.2020 has furnished its reply. Deferred for comments of TE.			

62	**Case No.:148/6/82-ALC4/2019**	Party Name:THINQ PHARMA CRO LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00374/AM20/	RLA File :03/95/040/00338/AM20/	Lic.No/Date:0310830207 10.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

63	**Case No.:155/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00381/AM20/	RLA File :03/95/040/00335/AM20/	Lic.No/Date:0310830246 12.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Complete chemistry, material balance, % yield and molecular weight.** **(ii) Exact chemical name of Export Product.**			

Case No.:157/6/82-ALC4/2019	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00383/AM20/	RLA File :09/24/040/00187/AM20/	Lic.No/Date:0910067778 12.07.2019	

64 **Decision:** The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
2,6-Dihydroxy Acetophenone	1 kg	1	Resorcinol	1.77 kg
		2	Methyl Aceto Acetate	1.86 kg
		3	Chloroform	2.65 kg
		4	Toulene	1.32 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.:162/6/82-ALC4/2019	Party Name:ANG LIFESCIENCES INDIA LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00388/AM20/	RLA File :30/24/040/00064/AM20/	Lic.No/Date:3010104756 12.07.2019	

65 **Decision:** The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
STERILE CEFTRIAXONE SODIUM USP INJECTION CONTAINING CEFTRIAXONE NOT LESS THAN 500 MG The party will account for the net contents of input 80.17KG in the export product at the time of export in the shipping bills.	1 Vial	1	STERILE CEFTRIAXONE SODIUM USP41 With the condition that " the import of drugs under Advance Authorization is allowed subject to Registration procedure under Drug & Cosmetic Act."	0.58 Gram

RA concerned may take further necessary action as per above decision of NC.

66	**Case No.:160/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00386/AM20/	RLA File :03/95/040/00363/AM20/	Lic.No/Date:0310830298 15.07.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm:

(i) Complete chemistry, molecular weight and % yield.
(ii) Stoichiometric balance.

67	**Case No.:169/6/82-ALC4/2019**	Party Name:PRACHEM LABORATORIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00395/AM20/	RLA File :08/24/040/00123/AM20/	Lic.No/Date:0810145731 17.07.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.11.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, the case is deferred.

68	**Case No.:199/6/82-ALC4/2019**	Party Name:CIRON DRUGS & PHARMACEUTICALS P. LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00425/AM20/	RLA File :03/94/040/00312/AM20/	Lic.No/Date:0310830435 19.07.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	ERYTHROMYCIN ESTOLATE FOR ORAL SUSPENSION USP 60 ML (EACH 5 ML AFTER RECONSTITUTION CONTAIN ERYTHROMYCIN ESTOLATE USP-EQ TO ERYTHROMYCIN (125 MG) NET CONTENT : 1)ERYTHROMYCIN ESTOLATE :2,028.000 KILOGRAM	2028.000 kg (7,80,000 No. Bottles)	ERYTHROMYCIN ESTOLATE	2600 mg / 60 ml Bottle
2	ERYTHROMYCIN ESTOLATE FOR ORAL SUSPENSION USP 60 ML (EACH 5 ML AFTER RECONSTITUTION CONTAIN ERYTHROMYCIN ESTOLATE USP-EQ TO ERYTHROMYCIN (250 MG) NET CONTENT : 1)ERYTHROMYCIN ESTOLATE :6,240.000 KILOGRAM	6240.000 kg (12,00,000 No. Bottles)	ERYTHROMYCIN ESTOLATE	5200 mg / 60 ml Bottle)

RA concerned may take further necessary action as per above decision of NC.

69	**Case No.:215/6/82-ALC4/2019**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00441/AM20/	RLA File :31/83/040/00047/AM20/	Lic.No/Date:3110067483 24.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder on 07.08.2020 and Final Reminder on 16.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Application awaited from the firm.			

70	**Case No.:216/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00442/AM20/	RLA File :03/95/040/00413/AM20/	Lic.No/Date:0310830547 24.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Complete chemistry, material balance, % yield and molecular weight.** **(ii) Exact chemical name of Export Product.**			

71	**Case No.:220/6/82-ALC4/2019**	Party Name:BHARAT SERUMS & VACCINES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00446/AM20/	RLA File :03/94/040/00313/AM20/	Lic.No/Date:0310830591 25.07.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and after deliberation, it was decided to forward a copy of 4.07 application to Department of Biotechnology (DBT) for obtaining its comments.			

Case No.:221/6/82-ALC4/2019	Party Name:ALPHAMED FORMULATIONS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00447/AM20/	RLA File :09/24/040/00222/AM20/	Lic.No/Date:0910067834 25.07.2019	

72

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2018 dated 05.06.2018 against advance authorization No. 0910063771dated 08.06.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty. Allowed in mg/tablet
GURONSAN C EFFERVESCENT TABLETS; (Each Tablet Contains - Glucuronolactone 50 mg,Ascorbic Acid 300mg,Caffeine 50mg)	1 Number	1	Glucuronolactone OR D-Glucuronolactone (Synonym)	51.00
		2	Ascorbic Acid (Crystalline)	306.0
		3	Caffeine Anhydrous	51.00 mg
		4	Sodium Polyphosphate	50.0
		5	Sodium Hydrogen Carbonate OR Sodium Bicarbonate (Synonym)	950.0
		6	Gin Fizz Micron Flavour	30.0
		7	Macrogol 6000	135.00 mg
		8	Monosodium Fumarate	2000.00

RA concerned may take further necessary action as per above decision of Norms Committee.

Case No.:231/6/82-ALC4/2019	Party Name:SMS LIFESCIENCES INDIA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00457/AM20/	RLA File :09/24/040/00215/AM20/	Lic.No/Date:0910067841 26.07.2019	

73

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
EZETIMIBE INTERMEDIATE IV - (ETZ-IV)	1 kg	1	(S)-4-PHENYL-OXAZOLIDIN-2-ONE	0.45 kg
		2	IMMCALA-T2-150 (ENZYME)	0.066 kg
		3	METHYLENE DICHLORIDE	6.00 kg
		4	METHANOL	4.40 kg
		5	N-HEPTANE	3.20 kg
		6	TOLUENE	7.80 kg
		7	POTASSIUM HYDROXIDE FLAKES	0.90 kg
		8	ISO PROPYL ALCOHOL	3.00 kg
		9	DIMETHYL FORMAMIDE	0.40 kg

RA concerned may take further necessary action as per above decision of NC.

74	**Case No.:236/6/82-ALC4/2019**	Party Name:ACME GENERICS LLP	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00462/AM20/	RLA File :22/24/040/00031/AM20/	Lic.No/Date:2210016214 26.07.2019	
	Decision: Deferred for comments of TE.			

75	**Case No.:237/6/82-ALC4/2019**	Party Name:ACME GENERICS LLP	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00463/AM20/	RLA File :22/24/040/00030/AM20/	Lic.No/Date:2210016215 26.07.2019	
	Decision: Deferred for comments of TE.			

76	**Case No.:238/6/82-ALC4/2019**	Party Name:WOCKHARDT LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00464/AM20/	RLA File :03/95/040/00426/AM20/	Lic.No/Date:0310830632 29.07.2019	
	Decision: Deferred for comments of TE.			

77	**Case No.:243/6/82-ALC4/2019**	Party Name:MAHAVIR SYNTHESIS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00469/AM20/	RLA File :52/24/040/00023/AM20/	Lic.No/Date:5210043127 29.07.2019	
	Decision: Deferred for comments of TE.			

78	**Case No.:249/6/82-ALC4/2019**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00475/AM20/	RLA File :09/24/040/00232/AM20/	Lic.No/Date:0910067851 30.07.2019	
	Decision: Deferred for comments of TE.			

79	**Case No.:256/6/82-ALC4/2019**	Party Name:WEXFORD LABORATORIES P LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00482/AM20/	RLA File :07/24/040/00100/AM20/	Lic.No/Date:0710115236 01.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	CEFADROXIL 500MG CAPSULES	365300.000 Number	1	CEFADROXIL MONOHYDRATE COMPACTED-USP	186.303 kg
2	CEFADROXIL 250MG/5ML SUSPENSION 100ML BOTTLE	18228.000 Number	2	CEFADROXIL MONOHYDRATE PLAIN- USP	95.67 kg

RA concerned may take further necessary action as per above decision of NC.

80	**Case No.:257/6/82-ALC4/2019**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00483/AM20/	RLA File :09/24/040/00229/AM20/	Lic.No/Date:0910067855 01.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
S(+)-2-AMINOBUTYRAMIDE HYDROCHLORIDE	1 kg	1	PROPIONALDEHYDE	1.27 kg
		2	SODIUM CYANIDE	1.08 kg
		3	L(+) TARTARIC ACID	1.12 kg
		4	METHYLENE DI CHLORIDE	1.12 kg
		5	ACETONE	1.86 kg
		6	METHANOL	1.39 kg

RA concerned may take further necessary action as per above decision of NC.

81	**Case No.:264/6/82-ALC4/2019**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00490/AM20/	RLA File :31/83/040/00051/AM20/	Lic.No/Date:3110067490 02.08.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 16.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred

82	**Case No.:262/6/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00488/AM20/	RLA File :09/24/040/00244/AM20/	Lic.No/Date:0910067866 05.08.2019	
	Decision: Deferred for comments of TE.			

83	**Case No.:268/6/82-ALC4/2019**	Party Name:CHEMIESYNTH (VAPI)LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00494/AM20/	RLA File :03/94/040/00363/AM20/	Lic.No/Date:0310830809 05.08.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Exact chemical name of Export Product with molecular weight.** **(ii) Complete chemistry, molecular weight, material balance and % yield.**			

84	**Case No.:1/10/82-ALC4/2019**	Party Name:MALLADI DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00575/AM20/	RLA File :04/24/040/00089/AM20/	Lic.No/Date:0410166026 29.08.2019	
	Decision: Deferred for comments of TE.			

85	**Case No.:15/10/82-ALC4/2019**	Party Name:SRINI PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00589/AM20/	RLA File :09/24/040/00304/AM20/	Lic.No/Date:0910067970 05.09.2019	
	Decision: Deferred for comments of TE.			

86	**Case No.:16/10/82-ALC4/2019**	Party Name:VIVIN DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00590/AM20/	RLA File :09/24/040/00289/AM20/	Lic.No/Date:0910067973 05.09.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 16.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

87	**Case No.:18/10/82-ALC4/2019**	Party Name:CADILA PHARMACEUTICALS LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00592/AM20/	RLA File :08/24/040/00175/AM20/	Lic.No/Date:0810146100 05.09.2019	
	Decision: Deferred for comments of TE.			

88	**Case No.:19/10/82-ALC4/2019**	Party Name:MEHK CHEMICALS PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00593/AM20/	RLA File :03/95/040/00555/AM20/	Lic.No/Date:0310831392 06.09.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(i) Complete chemistry, molecular weight, % yield and material balance.**			

89	**Case No.:27/10/82-ALC4/2019**	Party Name:M/S HIMALAYAN PRODUCTS & INDUSTRIES CORPN., P.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00601/AM20/	RLA File :61/24/040/00007/AM20/	Lic.No/Date:6110001614 06.09.2019	
	Decision: Deferred for comments of TE.			

90	**Case No.:28/10/82-ALC4/2019**	Party Name:SRF LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00602/AM20/	RLA File :05/24/040/00296/AM20/	Lic.No/Date:0510411778 06.09.2019	
	Decision: Deferred for comments of TE.			

91	**Case No.:30/10/82-ALC4/2019**	Party Name:MANGALAM DRUGS AND ORGANICS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00604/AM20/	RLA File :03/95/040/00483/AM20/	Lic.No/Date:0310831434 09.09.2019	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019 against advance authorization No. 0310832757 dated 14.11.2019, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
PIPERAQUINE PHOSPHATE	1 kg	1	ETHOXY METHYLENE MALONIC ACID ESTER (EMME)	1.30 kg
		2	PIPERAZINE ANHYDROUS	0.832 kg

RA concerned may take further necessary action as per above decision of NC.

92	**Case No.:31/10/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00605/AM20/	RLA File :09/24/040/00307/AM20/	Lic.No/Date:0910067982 09.09.2019	

Decision: Deferred for comments of TE.

93	**Case No.:32/10/82-ALC4/2019**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00606/AM20/	RLA File :34/24/040/00111/AM20/	Lic.No/Date:3410045437 09.09.2019	

Decision: Deferred for comments of TE.

94	**Case No.:33/10/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00607/AM20/	RLA File :09/24/040/00309/AM20/	Lic.No/Date:0910067984 11.09.2019	

Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020:

(i) % yield at each stage of manufacturing.
(ii) Calculation Sheet for requirement of quantity asked on the basis of % yield and molecular weight.

In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.

Case No.:34/10/82-ALC4/2019	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00608/AM20/	RLA File :09/24/040/00310/AM20/	Lic.No/Date:0910067989 11.09.2019	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 2/82-ALC4/2020 dated 10.07.2020 against advance authorization No. 0910067270 dated 13.03.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

95

Export product	Qty.	Sl. No.	Import items	Qty.
VELPATASVIR-COPOVIDONE (1:1)	1 kg	1	Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4,3 6,7] naphtha[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl)carbamate	0.555 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

Case No.:37/10/82-ALC4/2019	Party Name:MANKIND PHARMA LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00611/AM20/	RLA File :05/24/040/00336/AM20/	Lic.No/Date:0510411802 11.09.2019	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2020 dated 07.08.2020 against advance authorization No. 0510410328 dated 23.04.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

96

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	CLOMIPRAMINE HCL CAPSULES, USP 25 MG	1 Number	1	CLOMIPRAMINE HCL USP	25.50 mg/ 25 mg capsule
2	CLOMIPRAMINE HCL CAPSULES, USP 50 MG	1 Number	1	CLOMIPRAMINE HCL USP	51.00 mg / 50 mg capsule
3	CLOMIPRAMINE HCL CAPSULES, USP 75 MG	1 Number	1	CLOMIPRAMINE HCL USP	76.50 mg/ 75 mg capsule

RA concerned may take further necessary action as per above decision of Norms Committee.

97	**Case No.:38/10/82-ALC4/2019**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00612/AM20/	RLA File :03/94/040/00455/AM20/	Lic.No/Date:0310831483 11.09.2019	
	Decision: Deferred for comments of TE.			

98	**Case No.:43/10/82-ALC4/2019**	Party Name:KEVA FRAGRANCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00617/AM20/	RLA File :03/94/040/00462/AM20/	Lic.No/Date:0310831524 13.09.2019	
	Decision: Deferred for comments of TE.			

99	**Case No.:48/10/82-ALC4/2019**	Party Name:ENCUBE ETHICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00622/AM20/	RLA File :03/94/040/00395/AM20/	Lic.No/Date:0310831546 13.09.2019	
	Decision: Deferred for comments of TE.			

100	**Case No.:51/10/82-ALC4/2019**	Party Name:ALPHAMED FORMULATIONS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00625/AM20/	RLA File :09/24/040/00313/AM20/	Lic.No/Date:0910067997 13.09.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

101	**Case No.:54/10/82-ALC4/2019**	Party Name:SANDHYA ORGANIC CHEMICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00628/AM20/	RLA File :03/95/040/00423/AM20/	Lic.No/Date:0310831560 16.09.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
DI . PHENYL ISODECYL PHOSPHITE (DPDP)	1 kg	1	PHENOL	0.557 kg
		2	ISODECYL ALCOHOL	0.419 kg
		3	YELLOW PHOSPHROUS	0.087 kg

RA concerned may take further necessary action as per above decision of NC.

102	**Case No.:55/10/82-ALC4/2019**	Party Name:SANDHYA ORGANIC CHEMICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00629/AM20/	RLA File :03/95/040/00425/AM20/	Lic.No/Date:0310831562 16.09.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
TRIPHENYL PHOSPHITE	1 kg	1	PHENOL	0.937 kg
		2	YELLOW PHSOPHORUS	0.1 kg

RA concerned may take further necessary action as per above decision of NC.

103	**Case No.:56/10/82-ALC4/2019**	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00630/AM20/	RLA File :08/24/040/00172/AM20/	Lic.No/Date:0810146177 16.09.2019	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 4/82-ALC4/2020 dated 18.09.2020 against advance authorization No. 0810143413 dated 07.09.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import Items	Qty. allowed in mg for 1 Number Tablet		
				12.5 mg	25.0 mg	50.0 mg
PROMETHAZINE HYDROCHLORIDE TABLETS USP 12.5 MG / 25 MG / 50 MG Tablet	1 Number Tablet	1	PROMETHAZINE HYDROCHLORIDE USP	12.75 mg	25.50 mg	51.0 mg
		2	HYDROXY PROPYL CELLULOSE (LOW SUBSTITUTE)	2.00 mg	4.00 mg	8.00 mg
		3	HYDROXYPROPYL CELLULOSE NF (KLUCEL LF)	4.00 mg	8.00 mg	16.00 mg
		4	LACTOSE MONOHYDRATE NF/PH.EU	81.00 mg	162.00 mg	324.00 mg
		5	MAGNESIUM STEARATE PH.E/NF/JP	0.50 mg	1.00 mg	2.00 mg

RA concerned may take further necessary action as per above decision of Norms Committee.

Case No.:57/10/82-ALC4/2019	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00631/AM20/	RLA File :08/24/040/00173/AM20/	Lic.No/Date:0810146178 16.09.2019	

104

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 12/82-ALC4/2019 dated 17.01.2020 against advance authorization No. 0810141617 dated 27.12.2017, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	DIVALPROEX SODIUM SPRINKLE CAPSULES USP 125 MG (EACH CAPSULE CONTAIN 134.50 MG OF DIVALPROEX SODIUM USP EQUIVALENT TO 125 MG OF VALPORIC ACID) (ACTIVE INGREDIENT : DIVALPROEX SODIUM USP - NET WT. 1294.563 KGS)	9625000.000 Number	1	DIVALPROEX SODIUM USP	1295.75 kg
			2	HYPROMELLOSE 3 CPS, 2910 USP	122.12 kg
			3	MICROCRYSTALLINE CELLULOSE NF, PH.EUR	863.05 kg
			4	METHACRYLIC ACID COPOLY DISPER NF	1791.065 kg
			5	TRIETHYL CITRATE NF	53.75 kg
2	DIVALPROEX SODIUM DELAYED RELEASE TABLETS USP 125 MG (EACH TABLET CONTAIN 134.50 MG OF DIVALPROEX SODIUM USP EQUIVALENT TO 125 MG OF VALPORIC ACID) (ACTIVE INGREDIENT : DIVALPROEX SODIUM USP - NET WT. 591.800 KGS)	4400000.000	1	DIVALPROEX SODIUM USP	592.41 kg
			4	METHACRYLIC ACID COPOLY DISPER NF	205.72 kg
			5	TRIETHYL CITRATE NF	6.05 kg
			6	POVIDONE USP (K-30)	41.80 kg
			7	MICROCRYSTALLINE CELLULOSE NF/IP/PH.E/BP (AVICEL PH101)	232.96 kg
			8	MAGNESIUM STEARATE PH.E/NF/JP	10.424 kg
3	DIVALPROEX SODIUM DELAYED RELEASE TABLETS USP 250 MG (EACH TABLET CONTAIN 269 MG OF DIVALPROEX SODIUM USP,EQUIVALENT TO 250 MG OF VALPORIC ACID) (ACTIVE INGREDIENT : DIVALPROEX SODIUM USP - NET WT. 1062.550 KGS)	3950000.000 Number	1	DIVALPROEX SODIUM USP	1063.54 kg
			4	METHACRYLIC ACID COPOLY DISPER NF	316.00 kg
			5	TRIETHYL CITRATE NF	9.48 kg
			6	POVIDONE USP (K-30)	75.05 kg
			7	MICROCRYSTALLINE CELLULOSE NF/IP/PH.E/BP (AVICEL PH101)	418.185 kg
			8	MAGNESIUM STEARATE PH.E/NF/JP	18.76 kg
4	DIVALPROEX SODIUM DELAYED RELEASE TABLETS USP 500 MG (EACH TABLET CONTAIN 538 MG OF DIVALPROEX SODIUM USP EQUIVALENT TO 500 MG OF VALPORIC ACID) (ACTIVE INGREDIENT : DIVALPROEX SODIUM USP - NET WT. 1587.100 KGS)	2950000.000 Number	1	DIVALPROEX SODIUM USP	1588.575 kg
			4	METHACRYLIC ACID COPOLY DISPER NF	472.00 kg
			5	TRIETHYL CITRATE NF	14.16 kg
			6	POVIDONE USP (K-30)	112.10 kg
			7	MICROCRYSTALLINE CELLULOSE NF/IP/PH.E/BP (AVICEL PH101)	624.66 kg
			8	MAGNESIUM STEARATE PH.E/NF/JP	28.025 kg

5	DIVALPROEX SODIUM EXTENDED RELEASE TABLETS USP 250 MG (EACH TABLET CONTAIN 269 MG OF DIVALPROEX SODIUM USP EQUIVALENT TO 250 MG OF VALPORIC ACID) (ACTIVE INGREDIENT : DIVALPROEX SODIUM USP - NET WT. 2165.450 KGS)	8050000.000 Number	1	DIVALPROEX SODIUM USP	2167.46 kg
			8	MAGNESIUM STEARATE PH.E/NF/JP	74.5 kg
			9	HYPROMELLOSE 15000 CPS, 2208 USP	1835.40 kg
			10	HYPROMELLOSE 5 CPS, 2910 USP	338.10 kg
			11	HYDROXYPROPYL CELLULOSE NF (KLUCEL HXF)	652.05 kg
			12	HYDROXYPROPYL CELLULOSE NF (KLUCEL EXF)	265.65 kg
6	DIVALPROEX SODIUM EXTENDED RELEASE TABLETS USP 500 MG (EACH TABLET CONTAIN 538 MG OF DIVALPROEX SODIUM USP EQUIVALENT TO 500 MG OF VALPORIC ACID) (ACTIVE INGREDIENT : DIVALPROEX SODIUM USP - NET WT. 3362.500 KGS)	6250000.000 Number	1	DIVALPROEX SODIUM USP	3365.625 kg
			8	MAGNESIUM STEARATE PH.E/NF/JP	115.69 kg
			9	HYPROMELLOSE 15000 CPS, 2208 USP	2850.00 kg
			10	HYPROMELLOSE 5 CPS, 2910 USP	525.00 kg
			11	HYDROXYPROPYL CELLULOSE NF (KLUCEL HXF)	1012.50 kg
			12	HYDROXYPROPYL CELLULOSE NF (KLUCEL EXF)	412.50 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

	Case No.:70/10/82-ALC4/2019	Party Name:THERAPIVA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
105	HQ File :01/82/050/00644/AM20/	RLA File :09/24/040/00294/AM20/	Lic.No/Date:0910068000 16.09.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 07.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.

	Case No.:71/10/82-ALC4/2019	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00645/AM20/	RLA File :09/24/040/00311/AM20/	Lic.No/Date:0910068001 16.09.2019	

106

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 4/82-ALC4/2020 dated 18.09.2020 against advance authorization No. 0910066086 dated 26.03.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
EMPAGLIFLOZIN-IH	1 kg	1	(1S)-1 5-Anhydro-1-C-[4-chloro -3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate OR (1S)-1 5-Anhydro-1-C-[4-chloro -3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol	1.525 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

107

	Case No.:63/10/82-ALC4/2019	Party Name:RENOWN PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00637/AM20/	RLA File :34/24/040/00182/AM20/	Lic.No/Date:3410045458 17.09.2019	

Decision: Deferred for comments of TE.

108

	Case No.:73/10/82-ALC4/2019	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00647/AM20/	RLA File :31/82/040/00056/AM20/	Lic.No/Date:3110067535 19.09.2019	

Decision: The firm vide e-mail dated 24.11.2020 has informed that due to current scenario of COVID-19, they are working with limited staff. The person handling all DGFT activities is not available for few days to send the required documents related to above mentioned Advance Authorisation. Accordingly, they have requested to allow them 45 days to send the required application.

The Committee considered the request of firm and decided to grant 45 days time to firm to furnish 4.07 application of subject Advance Authorization.

109	**Case No.:129/10/82-ALC4/2019**	Party Name:TRANSPEK INDUSTRY LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00703/AM20/	RLA File :34/24/040/00187/AM20/	Lic.No/Date:3410045471 20.09.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
2,4,6 TRIMETHYL BENZOYL CHLORIDE	1 kg	1	MESITYLENE	1.132 kg

RA concerned may take further necessary action as per above decision of NC.

110	**Case No.:131/10/82-ALC4/2019**	Party Name:TRANSPEK INDUSTRY LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00705/AM20/	RLA File :34/24/040/00189/AM20/	Lic.No/Date:3410045470 20.09.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vo.l. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
ISOPHTHALOYL CHLORIDE/TEREPHTHALOYL CHLORIDE MIXTURE (93%/7%)	1 kg	1	ISOPHTHALIC ACID	0.845 kg

RA concerned may take further necessary action as per above decision of NC.

111	**Case No.:78/10/82-ALC4/2019**	Party Name:STERLING AUXILIARIES PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00652/AM20/	RLA File :03/95/040/00621/AM20/	Lic.No/Date:0310831732 23.09.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 06.10.2020 has furnished its reply. Deferred for comments of TE.

112	**Case No.:176/10/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00750/AM20/	RLA File :09/24/040/00322/AM20/	Lic.No/Date:0910068026 23.09.2019	
	Decision: Deferred for comments of TE.			

113	**Case No.:79/10/82-ALC4/2019**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00653/AM20/	RLA File :09/24/040/00327/AM20/	Lic.No/Date:0910068031 24.09.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
DARUNAVIR PROPYLENE GLYCOLATE	1 kg	1	(2S,3S)-1,2-Epoxy-3-(Boc-amino)-4-phenylbutane (or) BOC-Epoxide	0.587 kg
		2	Activated Carbon (Carbon Enoanticromos)	0.100 kg
		3	[3R,3aS,6aR]-3-Hydroxyhexahydrofuro[2,3-b]furanyl succicinamidyl carbonate	0.480 kg
		4	Isobutylamine	0.330 kg
		5	Methanol (Methyl Alcohol)	1.92 kg
		6	Methylene Chloride	2.51 kg
		7	Toluene	0.77 kg
		8	Triethylamine	0.60 kg

RA concerned may take further necessary action as per above decision of NC.

114	**Case No.:82/10/82-ALC4/2019**	Party Name:DANOPHARM CHEMICALS PRIVATE LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00656/AM20/	RLA File :03/94/040/00422/AM20/	Lic.No/Date:0310831769 24.09.2019	
	Decision: Deferred for comments of TE.			

115	**Case No.:87/10/82-ALC4/2019**	Party Name:OPES HEALTH CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00661/AM20/	RLA File :08/24/040/00202/AM20/	Lic.No/Date:0810146231 25.09.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 20.11.2020 has furnished its reply. Deferred for comments of TE.			

116	**Case No.:96/10/82-ALC4/2019**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00670/AM20/	RLA File :03/94/040/00484/AM20/	Lic.No/Date:0310831860 27.09.2019	
	Decision: Deferred for comments of TE.			

117	**Case No.:97/10/82-ALC4/2019**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00671/AM20/	RLA File :03/94/040/00485/AM20/	Lic.No/Date:0310831861 27.09.2019	
	Decision: Deferred for comments of TE.			

118	**Case No.:98/10/82-ALC4/2019**	Party Name:O C SPECIALITIES PVT.LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00672/AM20/	RLA File :03/95/040/00625/AM20/	Lic.No/Date:0310831873 27.09.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: (i) Justification for quantity asked for import item No. 3 -5% Palladium on Carbon Paste Type 87, 5R 487 (Pd/C) on Dry Basis. (ii) Material balance on % metal content for export product No. 2 – Palladium Metal Sponge and import item No. 4 - RECOVERABLE WASTAGE GENERATED FROM 5% PALLADIUM ON CARBON PASTE TYPE 487,5R 487 (Pd/C) ON DRY BASIS. (iii) Production / Consumption Data till date for both export products separately duly certified by GST. In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

119	**Case No.:103/10/82-ALC4/2019**	Party Name:AVIK PHARMACEUTICAL LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00677/AM20/	RLA File :03/94/040/00494/AM20/	Lic.No/Date:0310831896 27.09.2019	
	Decision: Deferred for comments of TE.			

120	**Case No.:109/10/82-ALC4/2019**	Party Name:CHIRAG ENTERPRISE	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00683/AM20/	RLA File :24/24/040/00028/AM20/	Lic.No/Date:2410042868 27.09.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. Ias per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
CRUDE METHYL METHACRYLATE MONOMER	1 kg	1	ACRYLIC PLASTIC STRIPS / OFFCUTS	1.10 kg

RA concerned may take further necessary action as per above decision of NC.

121	**Case No.:110/10/82-ALC4/2019**	Party Name:GOPINATH CHEM-TECH LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00684/AM20/	RLA File :08/24/040/00190/AM20/	Lic.No/Date:0810146246 27.09.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.

Case No.:112/10/82-ALC4/2019	Party Name:SATYADEVA PHARMACEUTICALS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00686/AM20/	RLA File :09/24/040/00318/AM20/	Lic.No/Date:0910068049 27.09.2019	

122

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
(2S,3S,5S)-2-Amino-3-Hydroxy-5-(1-Tetra hydro pyramid-2-only)-3-Methyl butanoyl) Amino-1,6-diphenyl Hexane-s-pyro glutamate (THP)	1 kg	1	DAH-II	1.006 kg
		2	1,2 DIMETHOXYETHANE	6.74 kg
		3	SODIUM BOROHYDRIDE	0.406 kg
		4	METHANE SULFONIC ACID (OR)METHANESULPHONIC ACID	1.57 kg
		5	ISOPROPYL ALCOHOL	1.27 kg
		6	Triethanolamine (99%)	1.167 kg
		7	N.N-DIMETHYL ACETAMIDE (OR) DIMETHYL ACETAMIDE	1.60 kg
		8	L-VALINE	0.630 kg
		9	MCF	1.00 kg
		10	MDC	3.25 kg
		11	ACERLONITRILE	0.30 kg
		12	METHANOL	3.30 kg
		13	METHYL TETR-BUTYL ETHER (OR)TERTIARY BUTYL METHYL ETHER	2.445kg
		14	N,N-CARBONYL DIMIDAZOLE	0.443 kg
		15	AMMONIUMFORMATE	0.500 kg
		16	DIMETHYL FORMAMIDE	3.945 kg
		17	L-PYROGLUTAMIC ACID	0.295 kg
		18	AMMONIUM CHLORIDE	2.00 kg
		19	PALLADIUM SPONGE (99.95% MIN)	0.001 kg

RA concerned may take further necessary action as per above decision of NC.

123	**Case No.:113/10/82-ALC4/2019**	Party Name:STERLING AUXILIARIES PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00687/AM20/	RLA File :03/95/040/00340/AM20/	Lic.No/Date:0310831915 30.09.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: **(i) Recovery of Methanol and its Commercial Value for in production of Export Product No. 1 - STEROCARE CMEA (Coco Mono Ethanol Amide).** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

124	**Case No.:114/10/82-ALC4/2019**	Party Name:STERLING AUXILIARIES PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00688/AM20/	RLA File :03/95/040/00135/AM20/	Lic.No/Date:0310831916 30.09.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: **(i) Blend ratio of Export Product No. 3 - M 2653 (OXYALKYLATED NONYL PHENOL+p-TERT.BUTYL PHENOL FORMADEHYDE RESIN).** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

125	**Case No.:115/10/82-ALC4/2019**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00689/AM20/	RLA File :31/83/040/00087/AM20/	Lic.No/Date:3110067548 30.09.2019	
	Decision: Deferred for comments of TE.			

126	**Case No.:120/10/82-ALC4/2019**	Party Name:TADIMETY AROMATICS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00694/AM20/	RLA File :07/24/040/00141/AM20/	Lic.No/Date:0710115523 03.10.2019	
	Decision: Deferred for comments of TE.			

127	**Case No.:122/10/82-ALC4/2019**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00696/AM20/	RLA File :03/94/040/00514/AM20/	Lic.No/Date:0310832013 04.10.2019	
	Decision: Deferred for comments of TE.			

128	**Case No.:140/10/82-ALC4/2019**	Party Name:LINK PHARMA CHEM LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00714/AM20/	RLA File :34/24/040/00099/AM20/	Lic.No/Date:3410045519 07.10.2019	
	Decision: Deferred for comments of TE.			

129	**Case No.:145/10/82-ALC4/2019**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00719/AM20/	RLA File :05/24/040/00377/AM20/	Lic.No/Date:0510412070 10.10.2019	
	Decision: Deferred for comments of TE.			

130	**Case No.:146/10/82-ALC4/2019**	Party Name:RAJASTHAN ANTIBIOTICS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Rejected**
	HQ File :01/82/050/00720/AM20/	RLA File :05/24/040/00357/AM20/	Lic.No/Date:0510412071 10.10.2019	
	Decision: The Committee considered the case as per agenda and in light of reply received from firm and it was observed that the DML for mixture of Ampicillin Sodium Sterile + Sulbactam Sodium Sterile is not found in the list of Approved items. In view of above, the Committee decided to **reject** the case.			

131	**Case No.:147/10/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00721/AM20/	RLA File :03/94/040/00541/AM20/	Lic.No/Date:0310832145 11.10.2019	
	Decision: Deferred for comments of TE.			

132	**Case No.:171/10/82-ALC4/2019**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00745/AM20/	RLA File :03/94/040/00566/AM20/	Lic.No/Date:0310832312 18.10.2019	
	Decision: Deferred for comments of TE.			

133	**Case No.:173/10/82-ALC4/2019**	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00747/AM20/	RLA File :03/94/040/00518/AM20/	Lic.No/Date:0310832317 18.10.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
4-HYDROXYBENZYL ALCOHOL	1 kg	1	4-HYDROXYBENZALDEHYDE OR PARA HYDROXY BENZALDEHYDE	1.2 kg
		2	SODIUM BOROHYDRIDE	0.23 kg

RA concerned may take further necessary action as per above decision of NC.

134	**Case No.:179/10/82-ALC4/2019**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00753/AM20/	RLA File :05/24/040/00410/AM20/	Lic.No/Date:0510412195 21.10.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and after deliberation, it was decided to forward a copy of 4.07 application to Department of Biotechnology (DBT) for obtaining its comments.			

135	**Case No.:186/10/82-ALC4/2019**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00760/AM20/	RLA File :34/24/040/00173/AM20/	Lic.No/Date:3410045560 22.10.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm:

(i) **Production / Consumption Data from GST Authorities for imported inputs for the licensing period.**

136	**Case No.:188/10/82-ALC4/2019**	Party Name:SPC LIFE SCIENCES PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00762/AM20/	RLA File :34/24/040/00143/AM20/	Lic.No/Date:3410045565 23.10.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

137	**Case No.:189/10/82-ALC4/2019**	Party Name:MENTHA & ALLIED PRODUCTS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00763/AM20/	RLA File :05/24/040/00375/AM20/	Lic.No/Date:0510412231 23.10.2019	
	Decision: Deferred for comments of TE.			

138	**Case No.:191/10/82-ALC4/2019**	Party Name:ASHISH LIFE SCIENCE PVT.LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00765/AM20/	RLA File :03/94/040/00526/AM20/	Lic.No/Date:0310832396 23.10.2019	
	Decision: Deferred for comments of TE.			

139	**Case No.:194/10/82-ALC4/2019**	Party Name:NATURAL AND ESSENTIAL OILS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00768/AM20/	RLA File :07/24/040/00158/AM20/	Lic.No/Date:0710115596 24.10.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: **(i) Net content of Chlorogenic Acid in import item.** **(ii) COA of import item from Foreign Supplier.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

Case No.:198/10/82-ALC4/2019	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/00772/AM20/	RLA File :09/24/040/00376/AM20/	Lic.No/Date:0910068138 28.10.2019	

140

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
S(+)-2-AMINOBUTYRAMIDE HYDROCHLORIDE	1 kg	1	PROPIONALDEHYDE	1.27 kg
		2	SODIUM CYANIDE	1.08 kg
		3	L(+) TARTARIC ACID	1.12 kg
		4	METHYLENE DI CHLORIDE	1.12 kg
		5	ACETONE	1.86 kg
		6	METHANOL	1.39 kg

RA concerned may take further necessary action as per above decision of NC.

	Case No.:212/10/82-ALC4/2019	Party Name:PORUS LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
141	HQ File :01/82/050/00786/AM20/	RLA File :09/24/040/00394/AM20/	Lic.No/Date:0910068157 04.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

	Case No.:213/10/82-ALC4/2019	Party Name:PORUS LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00787/AM20/	RLA File :09/24/040/00393/AM20/	Lic.No/Date:0910068158 04.11.2019	
142	**Decision:** The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 10/82-ALC4/2019 dated 29.11.2019, followed by Reminder on 20.01.2020 and Final Reminder on 06.10.2020. **(i) Complete chemical name of the export item.** **(ii) Complete 4E with all technical details i.e chemistry, molecular weight, stoichiometric reaction and % of yield on molar basis at every stage** **(iii) A copy of 4.07 application of subject advance authorization.** Hence, the case is deferred.			

	Case No.:214/10/82-ALC4/2019	Party Name:GRANDEUR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
143	HQ File :01/82/050/00788/AM20/	RLA File :05/23/040/00251/AM20/	Lic.No/Date:0510412350 05.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

	Case No.:217/10/82-ALC4/2019	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/00791/AM20/	RLA File :05/24/040/00439/AM20/	Lic.No/Date:0510412361 05.11.2019	

144

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 12/82-ALC4/2019 dated 17.01.2020 against advance authorization No. 0510406572 dated 23.05.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Azelastine Hydrochloride Nasal Solution (Nasal Spray) 0.1% (137 mcg per spray) 30ML (Each spray contains Azelastine Hydrochloride equivalent to 30.00mg) (Equivalent to 15600.000Grams of bulk drug)	520000.000 Number	1	Azelastine Hydrochloride (Relevant Bulk Drug)	14532.96 Gram
Azelastine Hydrochloride Ophthalmic Solution 0.05% W/V 6ML. (Each solution contains Azelastine Hydrochloride equivalent to 3.000 mg) (Equivalent to 720.000 Grams of bulk drug) (Equivalent to total 16320.000Grams of bulk drug)	240000.000 Number	1	Azelastine Hydrochloride (Relevant Bulk Drug)	734.40 Gram

RA concerned may take further necessary action as per above decision of Norms Committee.

	Case No.:223/10/82-ALC4/2019	Party Name:MAPAEX CONSUMER HEALTHCARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
145	HQ File :01/82/050/00797/AM20/	RLA File :56/24/040/00018/AM20/	Lic.No/Date:5610005722 07.11.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.

146	**Case No.:235/10/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00809/AM20/	RLA File :09/24/040/00407/AM20/	Lic.No/Date:0910068176 13.11.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 10/82-ALC4/2019 dated 29.11.2019, followed by Reminder on 20.01.2020 and Final Reminder on 06.10.2020: **(i) Complete chemical name of export product.** **(ii) Stepwise complete and balanced chemical reactions showing molecular weight and % yield on molar basis.** **(iii) Technical justification for the yields at various steps.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

147	**Case No.:238/10/82-ALC4/2019**	Party Name:ATUL LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00812/AM20/	RLA File :08/24/040/00258/AM20/	Lic.No/Date:0810146544 13.11.2019	
	Decision: Deferred for comments of TE.			

148	**Case No.:239/10/82-ALC4/2019**	Party Name:INDOCO REMEDIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00813/AM20/	RLA File :03/94/040/00587/AM20/	Lic.No/Date:0310832731 13.11.2019	
	Decision: Deferred for comments of TE.			

149	**Case No.:241/10/82-ALC4/2019**	Party Name:SMILAX LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00815/AM20/	RLA File :09/24/040/00411/AM20/	Lic.No/Date:0910068182 14.11.2019	
	Decision: Deferred for comments of TE.			

150	**Case No.:244/10/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00818/AM20/	RLA File :03/94/040/00636/AM20/	Lic.No/Date:0310832767 14.11.2019	
	Decision: Deferred for comments of TE.			

151	**Case No.:245/10/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00819/AM20/	RLA File :09/24/040/00414/AM20/	Lic.No/Date:0910068184 14.11.2019	
	Decision: Deferred for comments of TE.			

152	**Case No.:246/10/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00820/AM20/	RLA File :09/24/040/00403/AM20/	Lic.No/Date:0910068187 14.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

153	**Case No.:249/10/82-ALC4/2019**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00823/AM20/	RLA File :03/95/040/00791/AM20/	Lic.No/Date:0310832783 14.11.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020 and Reminder on 06.10.2020: **(i) Recovery of Methanol in kgs in the process and its commercial value.** **(ii) Justification for low yield of 63%.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

154	**Case No.:250/10/82-ALC4/2019**	Party Name:MANGALAM ORGANICS LIMITED FORMERLY DUJODWALA PRODU	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00824/AM20/	RLA File :03/95/040/00702/AM20/	Lic.No/Date:0310832785 14.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 12.10.2020 has furnished its reply. Deferred for comments of TE.			

155	**Case No.:252/10/82-ALC4/2019**	Party Name:CLARIANT INDIA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00826/AM20/	RLA File :03/94/040/00639/AM20/	Lic.No/Date:0310832792 14.11.2019	
	Decision: Deferred for comments of TE.			

156	**Case No.:247/10/82-ALC4/2019**	Party Name:VEKO CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00821/AM20/	RLA File :31/83/040/00104/AM20/	Lic.No/Date:3110067591 15.11.2019	
	Decision: Deferred for comments of TE.			

157	**Case No.:253/10/82-ALC4/2019**	Party Name:VINS BIOPRODUCTS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00827/AM20/	RLA File :09/24/040/00410/AM20/	Lic.No/Date:0910068189 15.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and after deliberation, it was decided to forward a copy of 4.07 application to Department of Biotechnology (DBT) for obtaining its comments.			

158	**Case No.:254/10/82-ALC4/2019**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00828/AM20/	RLA File :03/94/040/00628/AM20/	Lic.No/Date:0310832799 15.11.2019	
	Decision: Deferred for comments of TE.			

159	**Case No.:255/10/82-ALC4/2019**	Party Name:PORUS LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00829/AM20/	RLA File :09/24/040/00421/AM20/	Lic.No/Date:0910068191 15.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

160	**Case No.:258/10/82-ALC4/2019**	Party Name:WEXFORD LABORATORIES P LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00832/AM20/	RLA File :07/24/040/00178/AM20/	Lic.No/Date:0710115700 18.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

161	**Case No.:259/10/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00833/AM20/	RLA File :09/24/040/00424/AM20/	Lic.No/Date:0910068197 18.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

162	**Case No.:261/10/82-ALC4/2019**	Party Name:AVIEUM LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00835/AM20/	RLA File :31/83/040/00101/AM20/	Lic.No/Date:3110067594 18.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 14/82-ALC4/2019 dated 06.03.2020, followed by Reminder to firm on 14.08.2020 and Final Reminder on 06.10.2020 as per Policy Circular No. 23/2015-20, dated 15.05.2019. Hence, the case is deferred.			

163	**Case No.:262/10/82-ALC4/2019**	Party Name:REYAANSH HEALTHCARE	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00836/AM20/	RLA File :03/95/040/00757/AM20/	Lic.No/Date:0310832850 18.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 10.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

164	**Case No.:263/10/82-ALC4/2019**	Party Name:STERLING AUXILIARIES PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00837/AM20/	RLA File :03/95/040/00812/AM20/	Lic.No/Date:0310832853 19.11.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder on 06.10.2020: **(i) Exact specification and blend ratio of Export Product No. 1 and 2.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

165	**Case No.:266/10/82-ALC4/2019**	Party Name:OPTIMUS DRUGS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00840/AM20/	RLA File :09/24/040/00412/AM20/	Lic.No/Date:0910068203 19.11.2019	
	Decision: Deferred for comments of TE.			

166	**Case No.:267/10/82-ALC4/2019**	Party Name:AVIEUM LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00841/AM20/	RLA File :31/83/040/00108/AM20/	Lic.No/Date:3110067598 19.11.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 14.08.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

167	**Case No.:268/10/82-ALC4/2019**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/00842/AM20/	RLA File :09/24/040/00365/AM20/	Lic.No/Date:0910068207 20.11.2019	
	Decision: The Committee considered the case as per agenda and it was observed that the firm was issued Show Cause Notice vide letter dated 10.10.2019.			

Case No.:45/6/82-ALC4/2020	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01654/AM21/	RLA File :56/24/040/00023/AM20/	Lic.No/Date:5610005735 22.11.2019	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2020 dated 09.10.2020 against advance authorization No. 5610005606 dated 09.05.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

168

Export product	Qty.	Sl. No.	Import items	Qty.
4,4-DIHYDROXY BENZOPHENONE	1 kg	1	PARA CHLORO BENZOTRICHLORIDE	1.73 kg
		2	PHENOL	0.71 kg
		3	ALUMINIUM CHLORIDE	1.00 kg
		4	SODIUM HYDROXIDE	0.23 kg
		5	DICHLOROETHEN	2.50 kg
		6	CUPROUS CHLORIDE	0.10 kg
		7	METHYLE ALCOHOL	2.50 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

Case No.:44/6/82-ALC4/2020	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01653/AM21/	RLA File :56/24/040/00016/AM20/	Lic.No/Date:5610005778 10.01.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2020 dated 09.10.2020 against advance authorization No. 5610005606 dated 09.05.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

169

Export product	Qty.	Sl. No.	Import items	Qty.
4,4-DIHYDROXY BENZOPHENONE	1 kg	1	PARA CHLORO BENZOTRICHLORIDE	1.73 kg
		2	PHENOL	0.71 kg
		3	ALUMINIUM CHLORIDE	1.00 kg
		4	SODIUM HYDROXIDE	0.23 kg
		5	DICHLOROETHEN	2.50 kg
		6	CUPROUS CHLORIDE	0.10 kg
		7	METHYLE ALCOHOL	2.50 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

170	**Case No.:46/6/82-ALC4/2020**	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01655/AM21/	RLA File :56/24/040/00044/AM20/	Lic.No/Date:5610005845 16.03.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2020 dated 09.10.2020 against advance authorization No. 5610005606 dated 09.05.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
4,4-DIHYDROXY BENZOPHENONE	1 kg	1	PARA CHLORO BENZOTRICHLORIDE	1.73 kg
		2	PHENOL	0.71 kg
		3	ALUMINIUM CHLORIDE	1.00 kg
		4	SODIUM HYDROXIDE	0.23 kg
		5	DICHLOROETHEN	2.50 kg
		6	CUPROUS CHLORIDE	0.10 kg
		7	METHYLE ALCOHOL	2.50 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

171	**Case No.:38/6/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01647/AM21/	RLA File :03/95/040/01220/AM20/	Lic.No/Date:0310835578 20.03.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
YAPOX 2275 (DI-TERT-AMYLHYDROQUINONE)	1 kg	1	HYDROQUINONE	0.575 kg
		2	TERTIARY AMYL ALCOHOL	0.431 kg

RA concerned may take further necessary action as per above decision of NC.

172	**Case No.:1/3/82-ALC4/2020**	Party Name:ZEISS PHARMACEUTICALS PVT.LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01428/AM21/	RLA File :30/22/040/00037/AM21/	Lic.No/Date:3010105262 25.06.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

173	**Case No.:3/3/82-ALC4/2020**	Party Name:ALTA LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01430/AM21/	RLA File :03/94/040/00205/AM21/	Lic.No/Date:0310836920 29.06.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019 against advance authorization No. 0310832261 dated 16.10.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
SODIUM SALICYLATE	1 kg	1	SALICYLIC ACID	0.80 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

174	**Case No.:4/3/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01431/AM21/	RLA File :07/24/040/00092/AM21/	Lic.No/Date:0710116675 29.06.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

175	**Case No.:5/3/82-ALC4/2020**	Party Name:MANGALAM DRUGS AND ORGANICS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01432/AM21/	RLA File :03/95/040/00198/AM21/	Lic.No/Date:0310836938 29.06.2020	

Decision: Deferred for comments of TE.

176	**Case No.:6/3/82-ALC4/2020**	Party Name:SHIRDI CHEMICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01433/AM21/	RLA File :03/95/040/00196/AM21/	Lic.No/Date:0310836944 30.06.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

177	**Case No.:8/3/82-ALC4/2020**	Party Name:NAARI PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01435/AM21/	RLA File :05/24/040/00143/AM21/	Lic.No/Date:0510414507 30.06.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

178	**Case No.:9/3/82-ALC4/2020**	Party Name:NAARI PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01436/AM21/	RLA File :05/24/040/00144/AM21/	Lic.No/Date:0510414508 30.06.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

179	**Case No.:10/3/82-ALC4/2020**	Party Name:ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01437/AM21/	RLA File :03/94/040/00210/AM21/	Lic.No/Date:0310836960 30.06.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

180	**Case No.:11/3/82-ALC4/2020**	Party Name:MAHI DRUGS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01438/AM21/	RLA File :26/24/040/00003/AM21/	Lic.No/Date:2610012912 30.06.2020	
	Decision: Deferred for comments of TE.			

181	**Case No.:12/3/82-ALC4/2020**	Party Name:FDC LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01439/AM21/	RLA File :03/94/040/00216/AM21/	Lic.No/Date:0310836966 30.06.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019 against advance authorization No. 0310831779dated 25.09.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Import item	Qty.
BRIMONIDINE TARTRATE EYE DROPS 0.2% W/V 5ML	1 Number	BRIMONIDINE L-TARTRATE	0.0102 gm/vial

RA concerned may take further necessary action as per above decision of Norms Committee.

182	**Case No.:20/3/82-ALC4/2020**	Party Name:SRINI PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01447/AM21/	RLA File :09/24/040/00143/AM21/	Lic.No/Date:0910068917 30.06.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

183	**Case No.:13/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01440/AM21/	RLA File :03/94/040/00201/AM21/	Lic.No/Date:0310836986 01.07.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

184	**Case No.:14/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01441/AM21/	RLA File :03/94/040/00202/AM21/	Lic.No/Date:0310836987 01.07.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

185	**Case No.:15/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01442/AM21/	RLA File :03/94/040/00200/AM21/	Lic.No/Date:0310836988 01.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

186	**Case No.:16/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01443/AM21/	RLA File :03/94/040/00979/AM20/	Lic.No/Date:0310836990 01.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

187	**Case No.:17/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01444/AM21/	RLA File :03/94/040/01071/AM20/	Lic.No/Date:0310836991 01.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

188	**Case No.:18/3/82-ALC4/2020**	Party Name:TOJO VIKAS INTERNATIONAL PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01445/AM21/	RLA File :05/24/040/00149/AM21/	Lic.No/Date:0510414531 01.07.2020	
	Decision: Deferred for comments of TE.			

189	**Case No.:19/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01446/AM21/	RLA File :03/94/040/00157/AM21/	Lic.No/Date:0310837001 01.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

190	**Case No.:22/3/82-ALC4/2020**	Party Name:ENCEE AROMATICS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01449/AM21/	RLA File :32/24/040/00019/AM21/	Lic.No/Date:3210079591 02.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide e-mail dated 17.10.2020 has furnished its reply. Deferred for comments of TE.			

191	**Case No.:23/3/82-ALC4/2020**	Party Name:SAISONS TRADE & INDUSTRY PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01450/AM21/	RLA File :03/95/040/00201/AM21/	Lic.No/Date:0310837035 06.07.2020	
	Decision: Deferred for comments of TE.			

192	**Case No.:24/3/82-ALC4/2020**	Party Name:MANKIND PHARMA LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01451/AM21/	RLA File :05/24/040/00161/AM21/	Lic.No/Date:0510414565 06.07.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2020 dated 07.08.2020 against advance authorization No. 0510410328 dated 23.04.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	CLOMIPRAMINE HCL CAPSULES, USP 25 MG	1 Number	1	CLOMIPRAMINE HCL USP	25.50 mg/ 25 mg capsule
2	CLOMIPRAMINE HCL CAPSULES, USP 50 MG	1 Number	1	CLOMIPRAMINE HCL USP	51.00 mg / 50 mg capsule
3	CLOMIPRAMINE HCL CAPSULES, USP 75 MG	1 Number	1	CLOMIPRAMINE HCL USP	76.50 mg/ 75 mg capsule

RA concerned may take further necessary action as per above decision of Norms Committee.

193	**Case No.:26/3/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01453/AM21/	RLA File :03/94/040/01083/AM20/	Lic.No/Date:0310837056 07.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

194	**Case No.:27/3/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01454/AM21/	RLA File :31/83/040/00025/AM21/	Lic.No/Date:3110067787 07.07.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	0.97 kg
		2	Methanol	0.38 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.1 kg

RA concerned may take further necessary action as per above decision of NC.

195	**Case No.:35/3/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01462/AM21/	RLA File :09/24/040/00070/AM21/	Lic.No/Date:0910068942 07.07.2020	
	Decision: Deferred for comments of TE.			

196	**Case No.:28/3/82-ALC4/2020**	Party Name:SAVLA CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01455/AM21/	RLA File :03/95/040/00192/AM21/	Lic.No/Date:0310837078 08.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

197	**Case No.:29/3/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01456/AM21/	RLA File :03/94/040/00227/AM21/	Lic.No/Date:0310837081 08.07.2020	
	Decision: Deferred for comments of TE.			

198	**Case No.:30/3/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01457/AM21/	RLA File :31/83/040/00020/AM21/	Lic.No/Date:3110067788 08.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

199	**Case No.:31/3/82-ALC4/2020**	Party Name:KEVA FRAGRANCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01458/AM21/	RLA File :03/94/040/00218/AM21/	Lic.No/Date:0310837120 09.07.2020	
	Decision: Deferred for comments of TE.			

200	**Case No.:32/3/82-ALC4/2020**	Party Name:SHARON BIO MEDICINE LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01459/AM21/	RLA File :03/95/040/00141/AM21/	Lic.No/Date:0310837129 10.07.2020	
	Decision: Deferred for comments of TE.			

201	**Case No.:34/3/82-ALC4/2020**	Party Name:MANKIND PHARMA LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01461/AM21/	RLA File :05/24/040/00168/AM21/	Lic.No/Date:0510414600 10.07.2020	
	Decision: Deferred for comments of TE.			

202	**Case No.:36/3/82-ALC4/2020**	Party Name:LINK PHARMA CHEM LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01463/AM21/	RLA File :34/24/040/00085/AM21/	Lic.No/Date:3410046202 10.07.2020	
	Decision: Deferred for comments of TE.			

203	**Case No.:37/3/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01464/AM21/	RLA File :07/24/040/00102/AM21/	Lic.No/Date:0710116730 10.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

204	**Case No.:43/3/82-ALC4/2020**	Party Name:HETERO LABS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01470/AM21/	RLA File :09/24/040/00148/AM21/	Lic.No/Date:0910068954 10.07.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
(2S,3S,5S)-2-(2,6-DIMETHYL PHENOXYACETYL)AMINO-3-HYDROXY-5-AMINO-1,6-DIPHENYL HEXANE	1 kg	1	(2S,3S,5S)-2-amino-3-hydroxy-5-tert butyl carbonyl amino-1,6-diphenyl-hexane	1.345 kg
		2	METHANOL	0.40 kg
		3	Methylene Chloride	0.769 kg
		4	ETHYL BROMO ACETATE	0.84 kg
		5	2,6 XYLENOL	0.59 kg
		6	N N DI ISO PROPYL ETHER	0.27 kg

RA concerned may take further necessary action as per above decision of NC.

205	**Case No.:44/3/82-ALC4/2020**	Party Name:ALPHAMED FORMULATIONS P LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01471/AM21/	RLA File :09/24/040/00159/AM21/	Lic.No/Date:0910068951 10.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

206	**Case No.:45/3/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01472/AM21/	RLA File :09/24/040/00144/AM21/	Lic.No/Date:0910068952 10.07.2020	
	Decision: Deferred for comments of TE.			

207	**Case No.:38/3/82-ALC4/2020**	Party Name:KLJ PLASTICIZERS LIMITED.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01465/AM21/	RLA File :05/23/040/00071/AM21/	Lic.No/Date:0510414611 13.07.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
DI-BUTYL PHTHALATE (GRADE-M) (DBP-M) (PACKED IN 2554 NOS. OF HM-HDPE DRUMS MADE OF HDPE GRANULES (21,709.000 KGS. WITHOUT WASTAGE)) (EACH DRUM SHALL WEIGHT 8.5 KG AND STORAGE CAPACITY 235.000 KGS.)	1 kg	1	PHTHALIC ANHYDRIDE	0.56 kg
		2	SABUTOL	0.56 kg
		3	HDPE GRANULES (TOTAL WEIGHT = 22,794.450 KGS.)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC.

208	**Case No.:39/3/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01466/AM21/	RLA File :07/24/040/00105/AM21/	Lic.No/Date:0710116735 13.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

209	**Case No.:40/3/82-ALC4/2020**	Party Name:TIDE INDUSTRIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01467/AM21/	RLA File :34/24/040/00086/AM21/	Lic.No/Date:3410046210 13.07.2020	
	Decision: Deferred for comments of TE.			

210	**Case No.:41/3/82-ALC4/2020**	Party Name:ATUL LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01468/AM21/	RLA File :08/24/040/00075/AM21/	Lic.No/Date:0810148122 14.07.2020	
	Decision: Deferred for comments of TE.			

211	**Case No.:42/3/82-ALC4/2020**	Party Name:INTAS PHARMACEUTICALS LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01469/AM21/	RLA File :08/24/040/00077/AM21/	Lic.No/Date:0810148124 14.07.2020	
	Decision: Deferred for comments of TE.			

212	**Case No.:46/3/82-ALC4/2020**	Party Name:KEVA FRAGRANCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01473/AM21/	RLA File :03/94/040/00254/AM21/	Lic.No/Date:0310837163 14.07.2020	
	Decision: Deferred for comments of TE.			

213	**Case No.:47/3/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01474/AM21/	RLA File :03/94/040/00257/AM21/	Lic.No/Date:0310837175 14.07.2020	
	Decision: Deferred for comments of TE.			

214	**Case No.:48/3/82-ALC4/2020**	Party Name:THINQ PHARMA-CRO LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01475/AM21/	RLA File :03/95/040/00224/AM21/	Lic.No/Date:0310837203 15.07.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 14/82-ALC4/2019 dated 06.03.2020 against advance authorization No. 0310828192 dated 05.04.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Dimethyl Isosorbide	1 kg	1	Isosorbide	0.93 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

215	**Case No.:49/3/82-ALC4/2020**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01476/AM21/	RLA File :03/95/040/00051/AM21/	Lic.No/Date:0310837205 15.07.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

216	**Case No.:50/3/82-ALC4/2020**	Party Name:ABBOTT HEALTH CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01477/AM21/	RLA File :03/94/040/00211/AM21/	Lic.No/Date:0310837210 15.07.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019against advance authorization No. 0310827953 dated 27.03.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Fenofibrate Bulk Granulate	1 kg	1	Fenofibrate Micronized IH/Ph.Eur	0.320 kg
		2	Hypromellose (2910, 3 cps) Ph. Eur	0.0633 kg
		3	Docusate Sodium Ph.Eur	0.0062 kg
		4	Sucrose Ph.Eur	0.3124 kg
		5	Sodium Lauril Sulfate Ph.Eur	0.0216 kg
		6	Lactose Monohydrate Ph.Eur	0.2804 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

217	**Case No.:51/3/82-ALC4/2020**	Party Name:BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01478/AM21/	RLA File :03/94/040/00232/AM21/	Lic.No/Date:0310837216 15.07.2020	

Decision: Deferred for comments of TE.

218	**Case No.:52/3/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01479/AM21/	RLA File :03/94/040/00260/AM21/	Lic.No/Date:0310837228 16.07.2020	

Decision: Deferred for comments of TE.

219	**Case No.:55/3/82-ALC4/2020**	Party Name:STYRAX LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01482/AM21/	RLA File :09/24/040/00166/AM21/	Lic.No/Date:0910068964 17.07.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

220	**Case No.:53/3/82-ALC4/2020**	Party Name:MEHTA API PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01480/AM21/	RLA File :03/95/040/00231/AM21/	Lic.No/Date:0310837276 20.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

221	**Case No.:54/3/82-ALC4/2020**	Party Name:ASTRAL STERITECH PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01481/AM21/	RLA File :34/24/040/00096/AM21/	Lic.No/Date:3410046228 20.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

222	**Case No.:56/3/82-ALC4/2020**	Party Name:INNOVARE LABS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01483/AM21/	RLA File :09/24/040/00174/AM21/	Lic.No/Date:0910068965 20.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

Case No.:57/3/82-ALC4/2020	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01484/AM21/	RLA File :09/24/040/00199/AM21/	Lic.No/Date:0910068980 20.07.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 4/82-ALC4/2020 dated 18.09.2020 against advance authorization No. 0910066086 dated 26.03.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

223

Export Product	Qty.	Sl. No.	Import items	Qty.
EMPAGLIFLOZIN-IH	1 kg	1	(1S)-1 5-Anhydro-1-C-[4-chloro -3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate OR (1S)-1 5-Anhydro-1-C-[4-chloro -3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol	1.525 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

Case No.:58/3/82-ALC4/2020	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
HQ File :01/82/050/01485/AM21/	RLA File :05/24/040/00176/AM21/	Lic.No/Date:0510414657 21.07.2020	

224

Decision: Deferred for comments of TE.

Case No.:59/3/82-ALC4/2020	Party Name:ADVANCE PETROCHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
HQ File :01/82/050/01486/AM21/	RLA File :08/24/040/00095/AM21/	Lic.No/Date:0810148200 21.07.2020	

225 **Decision:** The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

Case No.:60/3/82-ALC4/2020	Party Name:BRAWN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	Status: Approved
HQ File :01/82/050/01487/AM21/	RLA File :05/23/040/00085/AM21/	Lic.No/Date:0510414674 21.07.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	AZITHROMYCIN CAPSULE 250 MG (HARD GELATIN CAPSULES CONTAINING WHITE CRANULAR POWDER)	1 Number	AZITHROMYCIN DIHYDRATE USP (WHITE OR ALMOST WHITE POWDER)	267.24 mg / 250 mg capsule
2	AZITHROMYCIN CAPSULE 500 MG (HARD GELATIN CAPSULES CONTAINING WHITE GRANULAR POWDER)	1 Number	AZITHROMYCIN DIHYDRATE USP (WHITE OR ALMOST WHITE POWDER)	534.48 mg / 500 mg capsule
3	AZITHROMYCIN TABLET 250MG (WHITE ROUND BICONVEX FILM COATED TABLETS)	1 Number	AZITHROMYCIN DIHYDRATE USP (WHITE OR ALMOST WHITE POWDER)	267.24 mg / 250 mg Tablet
4	AZITHROMYCIN TABLET 500 MG (WHITE ELONGATED BICONVEX SCORED ON ONE SIDE FILM COATED TABLETS)	1 Number	AZITHROMYCIN DIHYDRATE USP (WHITE OR ALMOST WHITE POWDER)	534.48 mg / 500 mg Tablet
5	AZITHROMYCIN ORAL SUSPENSION 200MG / 5ML-30ML (PINKISH WHITE GRANULAR POWDER FORMING PINK COLOURED SUSPENSION ON RECONSITITUTIN)	1 Number	AZITHROMYCIN DIHYDRATE USP (WHITE OR ALMOST WHITE POWDER)	1320.48 mg / 30 ml bottle

226

RA concerned may take further necessary action as per above decision of NC.

Case No.:67/3/82-ALC4/2020	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	Status: Deferred
HQ File :01/82/050/01494/AM21/	RLA File :09/24/040/00209/AM21/	Lic.No/Date:0910068983 21.07.2020	

227

Decision: Deferred for comments of TE.

228	**Case No.:68/3/82-ALC4/2020**	Party Name:STYRAX PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01495/AM21/	RLA File :09/24/040/00208/AM21/	Lic.No/Date:0910068986 21.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

229	**Case No.:41/6/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01650/AM21/	RLA File :09/24/040/00615/AM20/	Lic.No/Date:0910068985 21.07.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2020 dated 02.08.2019 against advance authorization No. 0310828072 dated 02.04.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
MEROPENEM FOR INJECTION (STERILE BULK) USP	1 kg	1	Meropenem Trihydrate (Non Sterile) I.P.	0.958 kg
		2	Aluminium Canisters / Bottles with Chloro Butyl Plug / Inner & Outer Lid and Gasket / Alu Caps [14 Ltrs (5Kg Cap)] (The firm has to account for packing material 2000 sets in the export product duly authenticated by customs authorities in the s.bills.)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC.

230	**Case No.:62/3/82-ALC4/2020**	Party Name:USV PRIVATE LIMITED (FORMERLY USV LIMITED)	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01489/AM21/	RLA File :03/95/040/00240/AM21/	Lic.No/Date:0310837311 22.07.2020	
	Decision: Deferred for comments of TE.			

231	**Case No.:63/3/82-ALC4/2020**	Party Name:SUPERMINT EXPORTS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01490/AM21/	RLA File :05/24/040/00191/AM21/	Lic.No/Date:0510414685 22.07.2020	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.			

232	**Case No.:64/3/82-ALC4/2020**	Party Name:USV PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01491/AM21/	RLA File :03/95/040/00236/AM21/	Lic.No/Date:0310837333 22.07.2020	
	Decision: Deferred for comments of TE.			

233	**Case No.:65/3/82-ALC4/2020**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01492/AM21/	RLA File :34/24/040/00098/AM21/	Lic.No/Date:3410046235 22.07.2020	
	Decision: Deferred for comments of TE.			

234	**Case No.:69/3/82-ALC4/2020**	Party Name:SYNTHO CHIRALS PVT. LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01496/AM21/	RLA File :09/24/040/00185/AM21/	Lic.No/Date:0910068991 22.07.2020	
	Decision: Deferred for comments of TE.			

235	**Case No.:66/3/82-ALC4/2020**	Party Name:ETERNIS FINE CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01493/AM21/	RLA File :03/94/040/00267/AM21/	Lic.No/Date:0310837390 23.07.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
METHYL - 3 - OXO - 2 - PENTYL - 1 - CYCLOPENTANE ACETATE	1 kg	1	PENTYL ENDO (85%) (2 Pentyl -2-Cyclopentene-1-one)	0.760 kg
		2	DIMETHYL MALONATE	0.660 kg
		3	SODIUM METHOXIDE	0.130 kg
		4	MS BARREL (Lacquered)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC.

236	**Case No.:70/3/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01497/AM21/	RLA File :05/24/040/00159/AM21/	Lic.No/Date:0510414709 24.07.2020	

Decision: Deferred for comments of TE.

237	**Case No.:71/3/82-ALC4/2020**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01498/AM21/	RLA File :34/24/040/00404/AM20/	Lic.No/Date:3410046248 24.07.2020	

Decision: Deferred for comments of TE.

238	**Case No.:72/3/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01499/AM21/	RLA File :03/94/040/00264/AM21/	Lic.No/Date:0310837414 27.07.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 4/82-ALC4/2019 dated 19.07.2019 against advance authorization No. 0310820244 dated 03.04.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.
Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray / Dymista Nasal Spray (Pack 120MD) Each Spray delivers: Azelastine Hydrochloride BP 137mcg Fluticasone Propionate 50mcg	1 Number

Sl. No.	Import items	Qty.
1	Azelastine Hydrochloride	16.44 mg
2	Fluticasone Propionate	6.00 mg
3	140 mcl pumps	Net + 1 %
4	25ml USP type 1 amber glass vial	Net + 1 %
5	Nasal actuator	Net to Net

RA concerned may take further necessary action as per above decision of Norms Committee.

239	**Case No.:74/3/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01501/AM21/	RLA File :07/24/040/00118/AM21/	Lic.No/Date:0710116798 27.07.2020	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm still has not furnished the 4.07 application asked for by NC-3 in its Meeting No. 3/82-ALC4/2020 dated 07.08.2020, followed by Reminder to firm on 18.09.2020 for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019. Hence, it was decided to issue **Final Reminder** to firm for furnishing a copy of 4.07 application as per policy circular no 23/2015-20 dated 15.05.2019.

240	**Case No.:1/6/82-ALC4/2020**	Party Name:SHITAL CHEMICAL INDUSTRIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01610/AM21/	RLA File :34/24/040/00140/AM21/	Lic.No/Date:3410046347 02.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

241	**Case No.:2/6/82-ALC4/2020**	Party Name:ATUL LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01611/AM21/	RLA File :08/24/040/00162/AM21/	Lic.No/Date:0810148472 03.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Amine Chain Extender	1 kg	1	Methanol	0.153 kg
		2	Ortho Ethyl Aniline (2 Ethyl Aniline)	1.058 kg

RA concerned may take further necessary action as per above decision of NC.

242	**Case No.:3/6/82-ALC4/2020**	Party Name:CADILA HEALTHCARE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01612/AM21/	RLA File :08/24/040/00158/AM21/	Lic.No/Date:0810148474 03.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.
1	PAROXETINE TABLETS USP 10 MG (ACTIVE INGREDIENT: PAROXETINE HCL HEMIHYDRATE USP EQUIVALENT TO PAROXETINE - NET WT. 1199.801 KGS. & GROSS WT. 1457.758 KGS.)	1 Number
2	PAROXETINE TABLETS USP 20 MG (ACTIVE INGREDIENT: PAROXETINE HCL HEMIHYDRATE USP EQUIVALENT TO PAROXETINE - NET WT. 4919.584 KGS. & GROSS WT. 5977.295 KGS.)	1 Number
3	PAROXETINE TABLETS USP 30 MG (ACTIVE INGREDIENT: PAROXETINE HCL HEMIHYDRATE USP EQUIVALENT TO PAROXETINE - NET WT. 2670.290 KGS. & GROSS WT. 3244.402 KGS.)	1 Number
4	PAROXETINE TABLETS USP 40 MG (ACTIVE INGREDIENT: PAROXETINE HCL HEMIHYDRATE USP EQUIVALENT TO PAROXETINE - NET WT. 4899.661 KGS. & GROSS WT. 5953.088 KGS.) (TOTAL NET WT. 13689.335 KGS. & GROSS WT. 16632.543 KGS OF. PAROXETINE HCL HEMIHYDRATE USP)	1 Number

Sl. No.	Import Items	For Export of 1 No. Tablet (Quantity in mg)			
		10 mg	20 mg	30 mg	40 mg
1.	PIPERIDINE ALCOHOL [(-) ALCOHOL] OR(-TRANS-1-N-METHYL-3-HYDROXY METHYL-4-(4-FLUORO PHENYL) PIPERIDINE	9.00 mg	18.00 mg	27.00 mg	36.00 mg
2	SODIUM STARCH GLYCOLATE NF	6.00 mg	12.00 mg	18.00 mg	24.00 mg
3	POVIDONE USP (K-30)	5.00 mg	10.00 mg	15.00 mg	20.00 mg
4	MAGNESIUM STEARATE PH.E/NF/JP	1.25 mg	2.50 mg	3.75 mg	5.00 mg
5	ANHYDROUS LACTOSE NF/BP	75.00 mg	150.00 mg	225.00 mg	300.00 mg
6	DIBASIC CALCIUM PHOSPHATE ANHYDROUS USP (THIS LICENCE IS ISSUED WITH CONDITION THAT IMPORT OF ANY DRUG AGAINST THIS LICENSE WILL BE ALLOWED THROUGH REGISTERED SOURCES AS PER PROVISION LAID DOWN IN DRUG & COSMETIC ACT AND AS PER PARA 4.07 OF HBP 2015-20 SUBJECT TO FIXATION OF NORMS BY ALC, NEW DELHI)	26.37 mg	52.74 mg	79.11 mg	105.48 mg

RA concerned may take further necessary action as per above decision of NC.

243	**Case No.:4/6/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01613/AM21/	RLA File :05/24/040/00255/AM21/	Lic.No/Date:0510415104 03.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

244	**Case No.:5/6/82-ALC4/2020**	Party Name:CONCORD BIOTECH LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01614/AM21/	RLA File :08/24/040/00395/AM20/	Lic.No/Date:0810148478 03.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

245

	Case No.:6/6/82-ALC4/2020	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01615/AM21/	RLA File :03/95/040/00343/AM21/	Lic.No/Date:0310838067 03.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
YALUB PA 135(3,5-DI-TERTIARY-BUTYL-4-HYDROXYHYDROCINNAMIC ACID)	1 kg	1	2,6-DI-TERTIARY-BUTYL PHENOL	0.825 kg
		2	METHYL ACRYLATE	0.349 kg
		3	EXXAL 8(ISO OCTANOL)	Not allowed, since not shown in the process.

RA concerned may take further necessary action as per above decision of NC.

246	**Case No.:7/6/82-ALC4/2020**	Party Name:AVIK PHARMACEUTICAL LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01616/AM21/	RLA File :03/94/040/00391/AM21/	Lic.No/Date:0310838076 03.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
BECLOMETHASONE DIPROPIONATE MICRONIZED (EP/BP/USP)	1 kg	1	PREGNA-1,4-DIEN-9,11-EPOXIDE-16 BETA METHYL-17 ALPHA,21-DIHYDROXYL-3,20-DIONE (DBXI) (CAS NO: 981-34-0) / 17 ALPHA 21-DIHYDROXY- 16-BETA METHYL- 9-BETA-11-BETA - EPOXY PREGNA-1, 4-DIENE-3, 20- DIONE (DB-XI) (CAS NO: 981-34-0)	0.88 kg

RA concerned may take further necessary action as per above decision of NC.

247	**Case No.:8/6/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01617/AM21/	RLA File :05/24/040/00248/AM21/	Lic.No/Date:0510415116 04.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

248	**Case No.:9/6/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01618/AM21/	RLA File :03/95/040/00350/AM21/	Lic.No/Date:0310838091 04.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

249	**Case No.:10/6/82-ALC4/2020**	Party Name:ZIM LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01619/AM21/	RLA File :03/95/040/00310/AM21/	Lic.No/Date:0310838114 07.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

250	**Case No.:11/6/82-ALC4/2020**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01620/AM21/	RLA File :07/24/040/00154/AM21/	Lic.No/Date:0710116964 07.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

251	**Case No.:12/6/82-ALC4/2020**	Party Name:CHIRAG ENTERPRISE	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01621/AM21/	RLA File :24/24/040/00040/AM21/	Lic.No/Date:2410043228 07.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

252	**Case No.:76/6/82-ALC4/2020**	Party Name:ZENITH DYEINTERMEDIATES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01685/AM21/	RLA File :03/95/040/00328/AM21/	Lic.No/Date:0310838112 07.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

253	**Case No.:13/6/82-ALC4/2020**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01622/AM21/	RLA File :07/24/040/00153/AM21/	Lic.No/Date:0710116971 08.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:14/6/82-ALC4/2020	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
254	HQ File :01/82/050/01623/AM21/	RLA File :31/83/040/00061/AM21/	Lic.No/Date:3110067847 08.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:15/6/82-ALC4/2020	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
255	HQ File :01/82/050/01624/AM21/	RLA File :31/83/040/00060/AM21/	Lic.No/Date:3110067848 08.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:16/6/82-ALC4/2020	Party Name:AMINES AND PLASTICIZERS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
256	HQ File :01/82/050/01625/AM21/	RLA File :03/94/040/00370/AM21/	Lic.No/Date:0310838163 08.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:17/6/82-ALC4/2020	Party Name:MANKIND PHARMA LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
257	HQ File :01/82/050/01626/AM21/	RLA File :05/24/040/00277/AM21/	Lic.No/Date:0510415162 09.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

258	**Case No.:18/6/82-ALC4/2020**	Party Name:VISWAAT CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01627/AM21/	RLA File :03/95/040/00327/AM21/	Lic.No/Date:0310838181 09.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

259	**Case No.:19/6/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01628/AM21/	RLA File :03/94/040/00341/AM21/	Lic.No/Date:0310838186 10.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

260	**Case No.:20/6/82-ALC4/2020**	Party Name:ANUPAM RASAYAN (INDIA) LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01629/AM21/	RLA File :52/24/040/00043/AM21/	Lic.No/Date:5210043532 10.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm: **(ii) Complete chemistry, molecular weight, % yield and stoichiometric balance.**			

261	**Case No.:21/6/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01630/AM21/	RLA File :03/94/040/00407/AM21/	Lic.No/Date:0310838188 10.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

262	**Case No.:22/6/82-ALC4/2020**	Party Name:STRATECHEM (INDIA) PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01631/AM21/	RLA File :03/95/040/00359/AM21/	Lic.No/Date:0310838204 10.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

263	**Case No.:27/6/82-ALC4/2020**	Party Name:ALTA LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01636/AM21/	RLA File :03/94/040/00422/AM21/	Lic.No/Date:0310838206 10.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

264	**Case No.:42/6/82-ALC4/2020**	Party Name:SRIAM LABS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01651/AM21/	RLA File :09/71/040/00084/AM21/	Lic.No/Date:0910069160 10.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

265	**Case No.:23/6/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01632/AM21/	RLA File :03/94/040/00340/AM21/	Lic.No/Date:0310838214 11.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

266

Case No.:24/6/82-ALC4/2020	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01633/AM21/	RLA File :03/94/040/00396/AM21/	Lic.No/Date:0310838231 11.09.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2019 dated 02.08.2019 against advance authorization No. 0310828072 dated 02.04.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
MEROPENEM FOR INJECTION(MEROPENEM BUFFERED STERILE)	1 kg	1	MEROPENEM NON-STERILE (MEROPENEM TRIHYDRATE NON-STERILE)	0.958 kg
		2	PACKING MATERIALS:ALUMINIUM CANISTER(5KG)/ALU.BOTL.ANO.2M(20L000T.8020XY)(ONE SET CONT.ONE CAN./ALU.BOTL.ANO. +IN LID+OUT LID+BROMO BUTYL GASKET/CHL.BUTYL PLUG 802/2T.802 AND TEAR OFF ALU CAP)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of Norms Committee.

267	**Case No.:25/6/82-ALC4/2020**	Party Name:ASTEC LIFESCIENCES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01634/AM21/	RLA File :03/94/040/00406/AM21/	Lic.No/Date:0310838227 11.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

268	**Case No.:26/6/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01635/AM21/	RLA File :03/94/040/00408/AM21/	Lic.No/Date:0310838219 11.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

269	**Case No.:52/6/82-ALC4/2020**	Party Name:ALPA LABORATORIES LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01661/AM21/	RLA File :56/24/040/00020/AM21/	Lic.No/Date:5610005946 11.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

270	**Case No.:47/6/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01656/AM21/	RLA File :09/24/040/00317/AM21/	Lic.No/Date:0910069173 14.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

271	**Case No.:53/6/82-ALC4/2020**	Party Name:KRITI NUTRIENTS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01662/AM21/	RLA File :56/24/040/00021/AM21/	Lic.No/Date:5610005948 14.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

272	**Case No.:48/6/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01657/AM21/	RLA File :03/94/040/00403/AM21/	Lic.No/Date:0310838273 15.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

273	**Case No.:49/6/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01658/AM21/	RLA File :03/94/040/00287/AM21/	Lic.No/Date:0310838274 15.09.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019 against advance authorization No. 0310832727 dated 13.11.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Sl. No.	Export Product	Qty.
1	GLIPIZIDE EXTENDED RELEASE TABLETS 10 MG. Each tablet contains (i) Glipizide USP- 10 mg (ii) Eastman (TM Cellulose Acetate (CA 398-10NF/EP)- 29.70 mg (iii) Sentry Polyox WSR N80 FP NF- 178.10 mg (iv) Sentry Polyox WSR 303 NF- 100 mg. Net content (i) 150.44 Kgs (ii) 446.81 Kgs (iii) 2679.37 Kgs (iv) 1504.42 Kgs.	1 Number
2	GLIPIZIDE EXTENDED RELEASE TABLETS 5 MG. Each tablet contains (i) Glipizide USP- 5 mg (ii) Eastman (TM Cellulose Acetate (CA 398-10NF/EP)- 20.40 mg (iii) Sentry Polyox WSR N80 FP NF- 89.05 mg (iv) Sentry Polyox WSR 303 NF- 50 mg. Net content (i) 58.70 Kgs (ii) 239.48 Kgs (iii) 1045.37 Kgs (iv) 586.96 Kgs.	1 Number
3	GLIPIZIDE EXTENDED RELEASE TABLETS 2.5 MG. Each tablet contains (i) Glipizide USP- 2.5 mg (ii) Eastman (TM Cellulose Acetate (CA 398-10NF/EP)- 20.40 mg (iii) Sentry Polyox WSR N80 FP NF- 89.05 mg (iv) Sentry Polyox WSR 303 NF- 50 mg. Net content (i) 11.06 Kgs (ii) 90.27 Kgs (iii) 394.03 Kgs (iv) 221.24 Kgs.	1 Number

Sl. No.	Import Items	For export of 1 Number of Tablet		
		2.5 mg	5.0 mg	10.0 mg
1	GLIPIZIDE USP	2.55 mg	5.10 mg	10.20 mg
2	EASTMAN (TM) CELLULOSE ACETATE (CA 398-10NF/EP)	20.40 mg	20.40 mg	29.70 mg
3	SENTRY POLYOX WSR N80 FP NF	89.05 mg	89.05 mg	178.10 mg
4	SENTRY POLYOX WSR 303 NF	50.00 mg	50.00 mg	100.00 mg

RA concerned may take further necessary action as per above decision of Norms Committee.

274	**Case No.:50/6/82-ALC4/2020**	Party Name:DANASHMAND ORGANIC PVT.LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01659/AM21/	RLA File :03/94/040/00441/AM21/	Lic.No/Date:0310838276 15.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
BENFOTHIAMINE	1 kg	1	THIAMINE HYDROCHLORIDE (VITAMIN B1 HCL.)	0.922 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

275	**Case No.:51/6/82-ALC4/2020**	Party Name:FINE ORGANIC INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01660/AM21/	RLA File :03/94/040/00426/AM21/	Lic.No/Date:0310838277 15.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm:

(i) Complete chemistry, material balance, molecular weight and % yield.
(ii) % wastage claimed.

276	**Case No.:54/6/82-ALC4/2020**	Party Name:VIBRANT PHARMACHEM PVT.LTD,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01663/AM21/	RLA File :07/24/040/00163/AM21/	Lic.No/Date:0710117014 15.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

277	**Case No.:55/6/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01664/AM21/	RLA File :09/24/040/00274/AM21/	Lic.No/Date:0910069187 15.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

278	**Case No.:56/6/82-ALC4/2020**	Party Name:PORUS LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01665/AM21/	RLA File :09/24/040/00332/AM21/	Lic.No/Date:0910069189 15.09.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2019 dated 02.08.2019against advance authorization No. 0910067601dated 30.05.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
2-Phenyl-3,3-bis(4-hydroxy phenyl)phthalimide (PPP-BP)	1 kg	1	PHTHALIC ANHYDRIDE	0.927 kg
		2	PHENOL	1.145 kg
		3	ZINC CHLORIDE	0.104 kg
		4	ANILINE	0.596 kg
		5	METHANOL	0.715 kg
		6	ACTIVATED CARBON	0.100 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

279	**Case No.:57/6/82-ALC4/2020**	Party Name:KEVA FRAGRANCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01666/AM21/	RLA File :03/94/040/00395/AM21/	Lic.No/Date:0310838311 16.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

280	**Case No.:58/6/82-ALC4/2020**	Party Name:VPL CHEMICALS PVT.LTD,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01667/AM21/	RLA File :07/24/040/00158/AM21/	Lic.No/Date:0710117023 17.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

281	**Case No.:59/6/82-ALC4/2020**	Party Name:M/S HIMALAYAN PRODUCTS & INDUSTRIES CORPN., P.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01668/AM21/	RLA File :05/24/040/00283/AM21/	Lic.No/Date:0510415240 17.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

282	**Case No.:60/6/82-ALC4/2020**	Party Name:VENKATA NARAYANA ACTIVE INGREDIENTS PRIVATE LIMITE	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01669/AM21/	RLA File :04/24/040/00098/AM21/	Lic.No/Date:0410167074 18.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

283	**Case No.:61/6/82-ALC4/2020**	Party Name:STERIL-GENE LIFE SCIENCES PRIVATE LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01670/AM21/	RLA File :04/24/040/00089/AM21/	Lic.No/Date:0410167077 18.09.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 14/82-ALC4/2018 dated 14.02.2019against advance authorization No. 0310819351dated 22.02.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
TAMOXIFEN 20 MG TABLETS (EOP 12 months As per Sl.No.7 Appendix 4J) (As per Para 4.07 of HBP)	1 Number	1	TAMOXIFEN CITRATE	31 mg/tablet

RA concerned may take further necessary action as per above decision of Norms Committee.

284	**Case No.:66/6/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01675/AM21/	RLA File :34/24/040/00171/AM21/	Lic.No/Date:3410046407 18.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

285	**Case No.:62/6/82-ALC4/2020**	Party Name:FDC LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01671/AM21/	RLA File :03/94/040/00421/AM21/	Lic.No/Date:0310838377 21.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

286	**Case No.:63/6/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01672/AM21/	RLA File :03/94/040/00431/AM21/	Lic.No/Date:0310838378 21.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

287	**Case No.:64/6/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01673/AM21/	RLA File :03/94/040/00430/AM21/	Lic.No/Date:0310838379 21.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

288	**Case No.:65/6/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01674/AM21/	RLA File :05/24/040/00295/AM21/	Lic.No/Date:0510415273 21.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

289	**Case No.:67/6/82-ALC4/2020**	Party Name:NASENSE LABS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01676/AM21/	RLA File :09/24/040/00306/AM21/	Lic.No/Date:0910069226 21.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

290	**Case No.:68/6/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01677/AM21/	RLA File :31/83/040/00058/AM21/	Lic.No/Date:3110067866 22.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

291	**Case No.:69/6/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01678/AM21/	RLA File :03/95/040/00378/AM21/	Lic.No/Date:0310838408 22.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

292	**Case No.:70/6/82-ALC4/2020**	Party Name:BIOLOGICAL E LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01679/AM21/	RLA File :09/24/040/00303/AM21/	Lic.No/Date:0910069236 22.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE. (ask TE whether to send it to DBT)			

293	**Case No.:73/6/82-ALC4/2020**	Party Name:SIDMAK LABORATORIES (INDIA) PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01682/AM21/	RLA File :52/24/040/00047/AM21/	Lic.No/Date:5210043542 22.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

294	**Case No.:74/6/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01683/AM21/	RLA File :09/24/040/00282/AM21/	Lic.No/Date:0910069242 22.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee considered the case as per agenda and it was observed that the firm was issued Show Cause Notice vide letter dated 10.10.2019.			

295	**Case No.:71/6/82-ALC4/2020**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01680/AM21/	RLA File :08/24/040/00186/AM21/	Lic.No/Date:0810148644 23.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

296	**Case No.:72/6/82-ALC4/2020**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01681/AM21/	RLA File :08/24/040/00187/AM21/	Lic.No/Date:0810148645 23.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

297

	Case No.:75/6/82-ALC4/2020	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01684/AM21/	RLA File :31/83/040/00068/AM21/	Lic.No/Date:3110067868 23.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	0.97 kg
		2	Methanol	0.38 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.1 kg

RA concerned may take further necessary action as per above decision of NC.

298	**Case No.:77/6/82-ALC4/2020**	Party Name:NAARI PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01686/AM21/	RLA File :05/24/040/00299/AM21/	Lic.No/Date:0510415286 23.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

299	**Case No.:78/6/82-ALC4/2020**	Party Name:NAARI PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01687/AM21/	RLA File :05/24/040/00300/AM21/	Lic.No/Date:0510415287 23.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

300	**Case No.:79/6/82-ALC4/2020**	Party Name:MANKIND PHARMA LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01688/AM21/	RLA File :05/24/040/00308/AM21/	Lic.No/Date:0510415295 23.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

301	**Case No.:80/6/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01689/AM21/	RLA File :09/24/040/00344/AM21/	Lic.No/Date:0910069243 23.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

302	**Case No.:86/6/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01695/AM21/	RLA File :09/24/040/00305/AM21/	Lic.No/Date:0910069254 23.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee considered the case as per agenda and it was observed that the firm was issued Show Cause Notice vide letter dated 10.10.2019.

303	**Case No.:81/6/82-ALC4/2020**	Party Name:OTSUKA CHEMICAL INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01690/AM21/	RLA File :05/24/040/00304/AM21/	Lic.No/Date:0510415302 24.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
7-Phenylacetamideo -3-Chloromethyl Cephalosporanic Acid Para Methoxybenzyl Ester (GCLE) White/LightYellow Powder	1 kg	1	Penicillin G Potassium 1st Crystals White / LightYellow Powder	1.80 kg
		2	MethanolLiquid	1.50 kg
		3	Dimethyl Formamide Colourless Liquide	0.80 kg
		4	Methylene Chloride Colourless Liquide	1.50 kg
		5	2-Mercaptobenzothiazole Ceramish Powder	0.25 kg
		6	Isopropyl Alcohol Liquid	0.80 kg
		7	Sodium Benzene Sulfinate Powder	1.20 kg
		8	Para Anisic Alcohol (p_Methoxybenzyl Alcohol) Liquid	0.52 kg
		9	1,4 Dioxane liquide	1.20 kg

RA concerned may take further necessary action as per above decision of NC.

304	**Case No.:82/6/82-ALC4/2020**	Party Name:FINE ORGANIC INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01691/AM21/	RLA File :03/94/040/00451/AM21/	Lic.No/Date:0310838429 24.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information from the firm:

(i) Complete chemistry, material balance, molecular weight and % yield.
(ii) % wastage claimed.

305	**Case No.:83/6/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01692/AM21/	RLA File :05/24/040/00274/AM21/	Lic.No/Date:0510415306 24.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

306	**Case No.:84/6/82-ALC4/2020**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01693/AM21/	RLA File :03/94/040/00283/AM21/	Lic.No/Date:0310838453 24.09.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

307	**Case No.:87/6/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01696/AM21/	RLA File :09/24/040/00318/AM21/	Lic.No/Date:0910069256 24.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

308	**Case No.:88/6/82-ALC4/2020**	Party Name:SRIAM LABS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01697/AM21/	RLA File :09/24/040/00353/AM21/	Lic.No/Date:0910069259 24.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

309

Case No.:85/6/82-ALC4/2020	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:6/82-ALC4/2020 13.11.2020	Status: Approved
HQ File :01/82/050/01694/AM21/	RLA File :07/24/040/00125/AM21/	Lic.No/Date:0710117061 25.09.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 15/82-ALC4/2018 dated 22.03.2019against advance authorization No. 0710113284 dated 15.05.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
NORFLEX 100MGTABLETS - (Orphenadrine Citrate 100mg + Lactose 167mg + Aerosil 200 - 8mg + Ethyl Cellulose 20mg) (Orphen-1000.000+ Lactose-1670.000+Aerosil-80.000+Ethyl-200.000 KGS) No: Tablets: 10000000 BP/EP/USP/PH.EUR/NF/USNF	1 Number	1	ORPHENADRINE CITRATE BP/EP/USP/PH.EUR	102.00 mg/tablet
		2	PHARMATOSE R 130M MILLED LACTOSE MONOHYDRATE USP-NF/ PH.EUR/JP	167.00 mg/tablet
		3	ETHYL CELLULOSE N100 - BP/EP/USP/Ph.EUR/USNF	20.00 mg/tablet

RA concerned may take further necessary action as per above decision of NC.

310

Case No.:89/6/82-ALC4/2020	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	Status: Approved
HQ File :01/82/050/01698/AM21/	RLA File :34/24/040/00169/AM21/	Lic.No/Date:3410046419 25.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Clobetasol Propionate Cream , 0.05% 15 gm (net content of active ingredients = 210 gm)	28000.000 Number	1	Clobetasol Propionate USP (Micronized)	2547.45 Gram
2	Clobetasol Propionate Cream , 0.05% 30 gm (net content of active ingredients = 217.50 gm)	14500.000 Number			
3	Clobetasol Propionate Cream , 0.05% 45 gm (net content of active ingredients = 450 gm)	20000.000 Number			
4	Clobetasol Propionate Cream , 0.05% 60 gm (net content of active ingredients =1620 gm)	54000.000 Number			

RA concerned may take further necessary action as per above decision of NC.

311	**Case No.:90/6/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01699/AM21/	RLA File :03/94/040/00454/AM21/	Lic.No/Date:0310838501 28.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
STERILE CEFTRIAXONE SODIUM	1 kg	1	CEFTRIAXONE SODIUM (NON-STERILE)	1.04 kg
		2	PACKING MATERIAL:ALUMINIIUM CANISTER(10KG)/ALU.BOTTLE ANODIZED 2M(20L000T.8020XY) (ONE SET CONTAINS ONE CANISTER/ALU.BOTL ANO.+IN LID+OUT LID+BROMO BUTYL GASKET/CHLORO BUTYL PLUG 802/2 T.802 AND TEAR OFF ALU.CAP)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC.

312	**Case No.:91/6/82-ALC4/2020**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01700/AM21/	RLA File :03/95/040/00349/AM21/	Lic.No/Date:0310838513 28.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
1-BROMO-5-CHLOROPENTANE	1 kg	1	1,5 PENTANEDIOL	1.335 kg
		2	LIQUID BROMINE	2.310 kg

RA concerned may take further necessary action as per above decision of NC.

313	**Case No.:92/6/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01701/AM21/	RLA File :09/24/040/00275/AM21/	Lic.No/Date:0910069265 28.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

314	**Case No.:126/6/82-ALC4/2020**	Party Name:ZENITH DYEINTERMEDIATES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01735/AM21/	RLA File :03/95/040/00361/AM21/	Lic.No/Date:0310838514 28.09.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

315	**Case No.:93/6/82-ALC4/2020**	Party Name:U SQUARE LIFESCIENCE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01702/AM21/	RLA File :08/24/040/00169/AM21/	Lic.No/Date:0810148685 29.09.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 4/82-ALC4/2020 dated 18.09.2020 against advance authorization No. 0810144243 dated 07.01.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
CLINDAMYCIN INJECTION 600MG/4ML	1 Number	1	CLINDAMYCIN PHOSPHATE USP	831.13 mg

RA concerned may take further necessary action as per above decision of NC.

316	**Case No.:97/6/82-ALC4/2020**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01706/AM21/	RLA File :09/24/040/00071/AM21/	Lic.No/Date:0910069270 29.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
S(+)-2-AMINOBUTYRAMIDE HYDROCHLORIDE	1 kg	1	PROPIONALDEHYDE	1.27 kg
		2	SODIUM CYANIDE	1.08 kg
		3	L(+) TARTARIC ACID	1.12 kg
		4	METHYLENE DI CHLORIDE	1.12 kg
		5	ACETONE	1.86 kg
		6	METHANOL	1.39 kg

RA concerned may take further necessary action as per above decision of NC.

317	**Case No.:98/6/82-ALC4/2020**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01707/AM21/	RLA File :09/24/040/00171/AM21/	Lic.No/Date:0910069271 29.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
S(+)-2-AMINOBUTYRAMIDE HYDROCHLORIDE	1 kg	1	PROPIONALDEHYDE	1.27 kg
		2	SODIUM CYANIDE	1.08 kg
		3	L(+) TARTARIC ACID	1.12 kg
		4	METHYLENE DI CHLORIDE	1.12 kg
		5	ACETONE	1.86 kg
		6	METHANOL	1.39 kg

RA concerned may take further necessary action as per above decision of NC.

318	**Case No.:94/6/82-ALC4/2020**	Party Name:DHANUKA LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01703/AM21/	RLA File :05/23/040/00197/AM21/	Lic.No/Date:0510415370 30.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

319	**Case No.:95/6/82-ALC4/2020**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01704/AM21/	RLA File :03/94/040/00467/AM21/	Lic.No/Date:0310838594 30.09.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

320	**Case No.:99/6/82-ALC4/2020**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01708/AM21/	RLA File :09/24/040/00359/AM21/	Lic.No/Date:0910069285 30.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol(BIS-IV)	1 kg	1	2,3-dihydrofuran	1.05 kg
		2	Sodium borohydride	0.72 kg

RA concerned may take further necessary action as per above decision of NC.

321	**Case No.:100/6/82-ALC4/2020**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01709/AM21/	RLA File :09/24/040/00642/AM20/	Lic.No/Date:0910069286 30.09.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
S(+)-2-AMINOBUTYRAMIDE HYDROCHLORIDE	1 kg	1	PROPIONALDEHYDE	1.27 kg
		2	SODIUM CYANIDE	1.08 kg
		3	L(+) TARTARIC ACID	1.12 kg
		4	METHYLENE DI CHLORIDE	1.12 kg
		5	ACETONE	1.86 kg
		6	METHANOL	1.39 kg

RA concerned may take further necessary action as per above decision of NC.

322	**Case No.:101/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01710/AM21/	RLA File :09/24/040/00362/AM21/	Lic.No/Date:0910069287 30.09.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

323	**Case No.:96/6/82-ALC4/2020**	Party Name:USV PRIVATE LIMITED (FORMERLY USV LIMITED)	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01705/AM21/	RLA File :03/95/040/00386/AM21/	Lic.No/Date:0310838614 01.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Doxycycline Tablets, USP 100 MG 500 S (28,000 Bottles x 500 Per Bottles = 1,40,00,000 Tablets) (Net Content Weight = 1,400.000 Kgs)	1 Number Tablet	1	Doxycycline USP (Monohydrate)	102.908 mg / Tablet

RA concerned may take further necessary action as per above decision of NC.

324	**Case No.:102/6/82-ALC4/2020**	Party Name:ANLON HEALTHCARE PRIVATELIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01711/AM21/	RLA File :24/24/040/00050/AM21/	Lic.No/Date:2410043265 01.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

325	**Case No.:103/6/82-ALC4/2020**	Party Name:CADILA HEALTHCARE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01712/AM21/	RLA File :08/24/040/00207/AM21/	Lic.No/Date:0810148710 01.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

326	**Case No.:104/6/82-ALC4/2020**	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01713/AM21/	RLA File :03/94/040/00468/AM21/	Lic.No/Date:0310838628 01.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

Case No.:105/6/82-ALC4/2020	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	Status: Approved
HQ File :01/82/050/01714/AM21/	RLA File :03/94/040/00471/AM21/	Lic.No/Date:0310838631 01.10.2020	

327

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated29.11.2019 against advance authorization No. 0310832727 dated 13.11.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export Product

Sl. No.	Export Product	Qty.
1	GLIPIZIDE EXTENDED RELEASE TABLETS 10 MG. Each tablet contains (i) Glipizide USP- 10 mg (ii) Eastman (TM Cellulose Acetate (CA 398-10NF/EP)- 29.70 mg (iii) Sentry Polyox WSR N80 FP NF- 178.10 mg (iv) Sentry Polyox WSR 303 NF- 100 mg. Net content (i) 150.44 Kgs (ii) 446.81 Kgs (iii) 2679.37 Kgs (iv) 1504.42 Kgs.	1 Number
2	GLIPIZIDE EXTENDED RELEASE TABLETS 5 MG. Each tablet contains (i) Glipizide USP- 5 mg (ii) Eastman (TM Cellulose Acetate (CA 398-10NF/EP)- 20.40 mg (iii) Sentry Polyox WSR N80 FP NF- 89.05 mg (iv) Sentry Polyox WSR 303 NF- 50 mg. Net content (i) 58.70 Kgs (ii) 239.48 Kgs (iii) 1045.37 Kgs (iv) 586.96 Kgs.	1 Number
3	GLIPIZIDE EXTENDED RELEASE TABLETS 2.5 MG. Each tablet contains (i) Glipizide USP- 2.5 mg (ii) Eastman (TM Cellulose Acetate (CA 398-10NF/EP)- 20.40 mg (iii) Sentry Polyox WSR N80 FP NF- 89.05 mg (iv) Sentry Polyox WSR 303 NF- 50 mg. Net content (i) 11.06 Kgs (ii) 90.27 Kgs (iii) 394.03 Kgs (iv) 221.24 Kgs.	1 Number

Sl. No.	Import Items	For export of 1 Number of Tablet		
		2.5 mg	5.0 mg	10.0 mg
1	GLIPIZIDE USP	2.55 mg	5.10 mg	10.20 mg
2	EASTMAN (TM) CELLULOSE ACETATE (CA 398-10NF/EP)	20.40 mg	20.40 mg	29.70 mg
3	SENTRY POLYOX WSR N80 FP NF	89.05 mg	89.05 mg	178.10 mg
4	SENTRY POLYOX WSR 303 NF	50.00 mg	50.00 mg	100.00 mg

RA concerned may take further necessary action as per above decision of Norms Committee.

328	**Case No.:106/6/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01715/AM21/	RLA File :03/94/040/00455/AM21/	Lic.No/Date:0310838654 01.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
AZITHROMYCIN DIHYDRATE	1 kg	1	AZITHROMYCIN AMINE	1.00 kg
		2	ACETONE	0.90 kg

RA concerned may take further necessary action as per above decision of NC.

329	**Case No.:107/6/82-ALC4/2020**	Party Name:SATYADIVIS PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01716/AM21/	RLA File :09/24/040/00319/AM21/	Lic.No/Date:0910069294 01.10.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

330	**Case No.:108/6/82-ALC4/2020**	Party Name:ASTEC LIFESCIENCES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01717/AM21/	RLA File :03/94/040/00425/AM21/	Lic.No/Date:0310838661 05.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

331

Case No.:109/6/82-ALC4/2020	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01718/AM21/	RLA File :03/94/040/00475/AM21/	Lic.No/Date:0310838683 05.10.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 6/82-ALC4/2019 dated 16.08.2019 against advance authorization No. 0310805840 30.06.2016, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 Number of Capsule	1	POTASSIUM CHLORIDE USP	765.0 mg
		2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
		3	DIBUTYL SEBACATE NF	12.0 mg
		4	ETHANOL USP 99.9%	2.62 ml
		5	100CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC	Relevant as per packing policy
		6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	
		7	53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (100 Count) (500 Count) 750mg	

RA concerned may take further necessary action as per above decision of Norms Committee.

332

Case No.:110/6/82-ALC4/2020	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01719/AM21/	RLA File :03/95/040/00052/AM21/	Lic.No/Date:0310838696 05.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
1-BROMO-5-CHLOROPENTANE	1 kg	1	1,5 PENTANEDIOL	1.335 kg
		2	LIQUID BROMINE	2.310 kg

RA concerned may take further necessary action as per above decision of NC.

	Case No.:111/6/82-ALC4/2020	Party Name:RENOWN PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
333	HQ File :01/82/050/01720/AM21/	RLA File :34/24/040/00182/AM21/	Lic.No/Date:3410046439 05.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

	Case No.:112/6/82-ALC4/2020	Party Name:S V LABS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01721/AM21/	RLA File :09/24/040/00181/AM21/	Lic.No/Date:0910069302 06.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

334

Export Product	Qty.	Sl. No.	Import items	Qty.
2R 5S-5 (4 Amino 5 fluoro 2 oxo 2H Pyrimidin 1 yl) [1,3] oxathiolane 2 carboxylic acid, 2S - isopropyl 5 R methyl 1R cyclohexyl ester	1 kg	1	GLYOXYLIC ACID-50%	0.68 kg
		2	2,5 DI HYDROXY 1,4 DITHIANE (DIOL)	0.28 kg
		3	5-FLUORO CYTOSINE	0.44 kg
		4	METHYLENE DICHLORIDE (MDC)	3.00 kg
		5	HEXAMETHYL DISILAZANE (HMDS)	0.53 kg

RA concerned may take further necessary action as per above decision of NC.

	Case No.:113/6/82-ALC4/2020	Party Name:S V LABS PVT LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01722/AM21/	RLA File :09/24/040/00310/AM21/	Lic.No/Date:0910069303 06.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

335

Export Product	Qty.	Sl. No.	Import items	Qty.
2R 5S-5 (4 Amino 5 fluoro 2 oxo 2H Pyrimidin 1 yl) [1,3] oxathiolane 2 carboxylic acid, 2S - isopropyl 5 R methyl 1R cyclohexyl ester	1 kg	1	GLYOXYLIC ACID-50%	0.68 kg
		2	2,5 DI HYDROXY 1,4 DITHIANE (DIOL)	0.28 kg
		3	5-FLUORO CYTOSINE	0.44 kg
		4	METHYLENE DICHLORIDE (MDC)	3.00 kg
		5	HEXAMETHYL DISILAZANE (HMDS)	0.53 kg

RA concerned may take further necessary action as per above decision of NC.

336	**Case No.:114/6/82-ALC4/2020**	Party Name:USV PRIVATE LIMITED (FORMERLY USV LIMITED)	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01723/AM21/	RLA File :03/95/040/00414/AM21/	Lic.No/Date:0310838714 06.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Griseofulvin Tablets USP 500 mg 100s (4,000 Bottles x 100 Per Bottle = 4,00,000 Tablets) (Net Content Weight = 200.000 kgs)	400000.000 Tablets	1	Griseofulvin USP	489.6 kg
2	Ultramicrosize Griseofulvin Tablets, USP 125 mg 100s (2,800 Bottles x 100 Per Bottle = 2,80,000 Tablets) (Net Content Weight = 35.000 kgs)	280000.000 Tablets			
3	Ultramicrosize Griseofulvin Tablets, USP 250 mg 100s (9,800 Bottles x 100 Per Bottle = 9,80,000 Tablets) (Net Content Weight = 245.000 kgs)	980000.000 Tablets			

RA concerned may take further necessary action as per above decision of NC.

337	**Case No.:115/6/82-ALC4/2020**	Party Name:HALDIA PETROCHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01724/AM21/	RLA File :02/24/040/00087/AM21/	Lic.No/Date:0210210144 06.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

338	**Case No.:116/6/82-ALC4/2020**	Party Name:ALEMBIC PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01725/AM21/	RLA File :34/24/040/00179/AM21/	Lic.No/Date:3410046451 07.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Haloperidol Tablets USP 0.5 mg (Net content of active ingredients 0.900 kgs)	1800000.000 Tablets	1	Haloperidol USP	48.654 kg
2	Haloperidol Tablets USP 1 mg (Net content of active ingredients 0.900 kgs)	900000.000 Tablets			
3	Haloperidol Tablets USP 2 mg (Net content of active ingredients 0.900 kgs)	450000.000 Tablets			
4	Haloperidol Tablets USP 5 mg (Net content of active ingredients 13.500 kgs)	2700000.000 Tablets			
5	Haloperidol Tablets USP 10 mg (Net content of active ingredients 18.000 kgs)	1800000.000 Tablets			
6	Haloperidol Tablets USP 20 mg (Net content of active ingredients 13.500 kgs)	675000.000 Tablets			

RA concerned may take further necessary action as per above decision of NC.

339

Case No.:117/6/82-ALC4/2020	Party Name:ALEMBIC PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01726/AM21/	RLA File :34/24/040/00180/AM21/	Lic.No/Date:3410046452 07.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Midodrine HCL Tabs USP 2.5 mg (Net content of active ingredients 4.500 kgs)	1800000.000 Tablets	1	Midodrine Hydrochloride USP (Micronized)	58.14 kg
2	Midodrine HCL Tabs USP 5 mg (Net content of active ingredients 22.500 kgs)	4500000.000 Tablets			
3	Midodrine HCL Tabs USP 10 mg (Net content of active ingredients 30.000 kgs)	3000000.000 Tablets			

RA concerned may take further necessary action as per above decision of NC.

340

Case No.:118/6/82-ALC4/2020	Party Name:FDC LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01727/AM21/	RLA File :03/94/040/00459/AM21/	Lic.No/Date:0310838763 07.10.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019against advance authorization No. 0310831779 25.09.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
BRIMONIDINE TARTRATE EYE DROPS 0.2% W/V 5ML (IOBRIM EYE DROPS 5ML)	1 Number	1	BRIMONIDINE L-TARTRATE	0.0102 gm/vial

RA concerned may take further necessary action as per above decision of Norms Committee.

341	**Case No.:119/6/82-ALC4/2020**	Party Name:SRI CHEMICALS	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01728/AM21/	RLA File :04/24/040/00109/AM21/	Lic.No/Date:0410167147 07.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

342	**Case No.:120/6/82-ALC4/2020**	Party Name:SRF LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01729/AM21/	RLA File :05/24/040/00333/AM21/	Lic.No/Date:0510415443 08.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

Case No.:121/6/82-ALC4/2020	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
HQ File :01/82/050/01730/AM21/	RLA File :03/94/040/00491/AM21/	Lic.No/Date:0310838803 08.10.2020	

343

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 6/82-ALC4/2018 dated 26.07.2018against advance authorization No. 0310813336 dated 17.05.2017, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Sl. No.	Export Product	Qty.
1	Desonide Cream 0.05% 15gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.375 Kgs)	1 Number
2	Desonide Cream 0.05% 60gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.900 Kgs)	1 Number
3	Desonide Lotion 0.05% 59ml (Net Wt. of Desonide USP Micronised (Sicor) is 0.885 Kgs)	1 Number
4	Desonide Lotion 0.05% 118ml (Net Wt. of Desonide USP Micronised (Sicor) is 1.770 Kgs)	1 Number
5	Desonide Ointment 0.05% 15gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.188 Kgs)	1 Number
6	Desonide Ointment 0.05% 60gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.750 Kgs)	1 Number

Sl. No.	**Import Items**	**For the Export of 1 No. Pack**					
		0.05% 15gm pack	0.05% 60gm pack	0.05% 59ml pack	0.05% 118ml pack	0.05% 15gm pack	0.05% 60gm pack
1	Desonide USP Micronised (Sicor)	0.00765 gm	0.0306 gm	0.301 gm	0.602 gm	0.00765 gm	0.0306 gm

RA concerned may take further necessary action as per above decision of Norms Committee.

344	**Case No.:122/6/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01731/AM21/	RLA File :31/83/040/00073/AM21/	Lic.No/Date:3110067877 08.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	0.97 kg
		2	Methanol	0.38 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.1 kg

RA concerned may take further necessary action as per above decision of NC.

345	**Case No.:123/6/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01732/AM21/	RLA File :09/24/040/00295/AM21/	Lic.No/Date:0910069305 08.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

346	**Case No.:124/6/82-ALC4/2020**	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01733/AM21/	RLA File :09/24/040/00328/AM21/	Lic.No/Date:0910069310 08.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

347	**Case No.:125/6/82-ALC4/2020**	Party Name:SMILAX LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Case Added**
	HQ File :01/82/050/01734/AM21/	RLA File :09/24/040/00358/AM21/	Lic.No/Date:0910069312 08.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

348	**Case No.:127/6/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01736/AM21/	RLA File :03/94/040/00490/AM21/	Lic.No/Date:0310838813 09.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

349	**Case No.:128/6/82-ALC4/2020**	Party Name:SUPERMINT EXPORTS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01737/AM21/	RLA File :05/24/040/00340/AM21/	Lic.No/Date:0510415463 09.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

350	**Case No.:129/6/82-ALC4/2020**	Party Name:BELCHEM INDUSTRIES INDIA PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01738/AM21/	RLA File :03/94/040/00504/AM21/	Lic.No/Date:0310838842 13.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

351	**Case No.:130/6/82-ALC4/2020**	Party Name:SWISS PARENTERALS LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01739/AM21/	RLA File :08/24/040/00227/AM21/	Lic.No/Date:0810148798 14.10.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
BENSERAZIDE HYDROCHLORIDE AND LEVODOPA CAPSULES BP 125MG (CO-BENELDOPA CAPSULES BP 25 MG / 100 MG) NET CONTENTS OF INPUT: 7.5 KGS..	300000.000 Number	1	BENSERAZIDE HYDROCHLORIDE USP/BP/IP/CEP/EP/ChP	7.65 kg

RA concerned may take further necessary action as per above decision of NC.

	Case No.:131/6/82-ALC4/2020	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01740/AM21/	RLA File :03/94/040/00505/AM21/	Lic.No/Date:0310838888 15.10.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019against advance authorization No. 0310827587 dated 11.03.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

352

Export product	Qty.	Sl. No.	Import items	Qty.
CEFEPIME FOR INJECTION	1 kg	1	CEFEPIME HCL (NON-STERILE)	0.655 kg
		2	ACETONE	1.816 kg
		3	L-ARGININE	0.37 kg
		4	ISO PROPYL ALCOHOL	0.392 kg
		5	PACKING MATERIAL:ALU. CANISTER(10KG)/ALUMINIUM BOTTLE ANODIZED 2M(20L000T.8020XY)(ONE SET CONT.ONE CAN./ALU.BOTL. ANO.	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of Norms Committee.

	Case No.:132/6/82-ALC4/2020	Party Name:ALTA LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
353	HQ File :01/82/050/01741/AM21/	RLA File :03/94/040/00536/AM21/	Lic.No/Date:0310838904 15.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

354	**Case No.:133/6/82-ALC4/2020**	Party Name:ROYAL PHARMA	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01742/AM21/	RLA File :03/95/040/00439/AM21/	Lic.No/Date:0310838908 15.10.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 15/82-ALC4/2019 dated 22.03.2019 against advance authorization No. 0310824487 dated 17.10.2018, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
BICALUTAMIDE SULFIDE CHEMICAL NAME: N-[4-CYANO-3-(TRIFLUORO METHYL)PHENYL]-3-[(4-FLUOROPHENYL THIO)] -2-HYDROXY-2-METHYL PROPIONALIDE	1 kg	1	N - [4-CYANO-3 - (TRIFLUOROMETHYL) PHENYL] METHACRYLAMIDE M. F C12H9ON2F3 M. Wt. 254	0.709 kg
		2	4- FLUOROTHIOPHENOL M. F C6H5F5 M. Wt. 128	0.30 kg

RA concerned may take further necessary action as per above decision of Norms Committee.

355	**Case No.:134/6/82-ALC4/2020**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01743/AM21/	RLA File :09/24/040/00272/AM21/	Lic.No/Date:0910069335 15.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

356	**Case No.:135/6/82-ALC4/2020**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01744/AM21/	RLA File :09/24/040/00273/AM21/	Lic.No/Date:0910069336 15.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

357	**Case No.:136/6/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01745/AM21/	RLA File :03/94/040/00392/AM21/	Lic.No/Date:0310838931 16.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

358	**Case No.:137/6/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01746/AM21/	RLA File :03/94/040/00516/AM21/	Lic.No/Date:0310838932 16.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

359	**Case No.:138/6/82-ALC4/2020**	Party Name:AVIK PHARMACEUTICAL LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Approved**
	HQ File :01/82/050/01747/AM21/	RLA File :03/94/040/00532/AM21/	Lic.No/Date:0310838937 16.10.2020	

Decision: The Committee considered the case as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2019 dated 29.11.2019 against advance authorization No. 0310831898 dated 27.09.2019, it was decided to ratify norms under Para 4.07 of HBP Vol. I as per details given below or as applied by the firm, whichever is less:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	CLOBETASOL 17 PROPIONATE EP/BP/USP	1 kg	BETAMETHASONE	1.00 kg
2	BETAMETHASONE DIPROPIONATE EP/BP/USP	1 kg	BETAMETHASONE	0.868 kg

RA concerned may take further necessary action as per above decision of NC.

360	**Case No.:139/6/82-ALC4/2020**	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01748/AM21/	RLA File :03/94/040/00514/AM21/	Lic.No/Date:0310838947 16.10.2020	

Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

	Case No.:140/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
361	HQ File :01/82/050/01749/AM21/	RLA File :03/94/040/01019/AM20/	Lic.No/Date:0310838949 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:141/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
362	HQ File :01/82/050/01750/AM21/	RLA File :03/94/040/00978/AM20/	Lic.No/Date:0310838950 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:142/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
363	HQ File :01/82/050/01751/AM21/	RLA File :03/94/040/00297/AM21/	Lic.No/Date:0310838951 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:143/6/82-ALC4/2020	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
364	HQ File :01/82/050/01752/AM21/	RLA File :03/94/040/00523/AM21/	Lic.No/Date:0310838952 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:144/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
365	HQ File :01/82/050/01753/AM21/	RLA File :03/94/040/00524/AM21/	Lic.No/Date:0310838953 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:145/6/82-ALC4/2020	Party Name:AVIK PHARMACEUTICAL LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
366	HQ File :01/82/050/01754/AM21/	RLA File :03/94/040/00531/AM21/	Lic.No/Date:0310838954 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:146/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
367	HQ File :01/82/050/01755/AM21/	RLA File :03/94/040/00184/AM21/	Lic.No/Date:0310838958 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:147/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
368	HQ File :01/82/050/01756/AM21/	RLA File :03/94/040/00825/AM20/	Lic.No/Date:0310838959 16.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:148/6/82-ALC4/2020	Party Name:NEON LABORATORIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
369	HQ File :01/82/050/01757/AM21/	RLA File :03/95/040/00409/AM21/	Lic.No/Date:0310838968 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:149/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
370	HQ File :01/82/050/01758/AM21/	RLA File :03/94/040/00525/AM21/	Lic.No/Date:0310838974 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:150/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
371	HQ File :01/82/050/01759/AM21/	RLA File :03/94/040/00528/AM21/	Lic.No/Date:0310838975 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:151/6/82-ALC4/2020	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
372	HQ File :01/82/050/01760/AM21/	RLA File :03/95/040/00053/AM21/	Lic.No/Date:0310838983 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

373	**Case No.:152/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01761/AM21/	RLA File :09/24/040/00382/AM21/	Lic.No/Date:0910069343 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

374	**Case No.:153/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01762/AM21/	RLA File :09/24/040/00383/AM21/	Lic.No/Date:0910069344 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

375	**Case No.:154/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01763/AM21/	RLA File :09/24/040/00381/AM21/	Lic.No/Date:0910069345 19.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

376	**Case No.:155/6/82-ALC4/2020**	Party Name:ANUH PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01764/AM21/	RLA File :03/94/040/00414/AM21/	Lic.No/Date:0310838998 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

377	**Case No.:156/6/82-ALC4/2020**	Party Name:ANUH PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01765/AM21/	RLA File :03/94/040/00415/AM21/	Lic.No/Date:0310838999 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:157/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
378	HQ File :01/82/050/01766/AM21/	RLA File :03/94/040/00548/AM21/	Lic.No/Date:0310839000 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:158/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
379	HQ File :01/82/050/01767/AM21/	RLA File :03/94/040/00526/AM21/	Lic.No/Date:0310839001 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:159/6/82-ALC4/2020	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
380	HQ File :01/82/050/01768/AM21/	RLA File :05/24/040/00355/AM21/	Lic.No/Date:0510415575 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

	Case No.:160/6/82-ALC4/2020	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
381	HQ File :01/82/050/01769/AM21/	RLA File :03/94/040/00527/AM21/	Lic.No/Date:0310839017 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

382	**Case No.:161/6/82-ALC4/2020**	Party Name:INNOVARE LABS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01770/AM21/	RLA File :26/24/040/00018/AM21/	Lic.No/Date:2610012921 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

383	**Case No.:162/6/82-ALC4/2020**	Party Name:SYNNAT PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01771/AM21/	RLA File :02/24/040/00094/AM21/	Lic.No/Date:0210210167 20.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

384	**Case No.:163/6/82-ALC4/2020**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01772/AM21/	RLA File :03/95/040/00202/AM21/	Lic.No/Date:0310839070 22.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

385	**Case No.:164/6/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01773/AM21/	RLA File :09/24/040/00356/AM21/	Lic.No/Date:0910069364 22.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee considered the case as per agenda and it was observed that the firm was issued Show Cause Notice vide letter dated 10.10.2019.			

386	**Case No.:165/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01774/AM21/	RLA File :09/24/040/00365/AM21/	Lic.No/Date:0910069368 22.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

387	**Case No.:166/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01775/AM21/	RLA File :09/24/040/00384/AM21/	Lic.No/Date:0910069369 22.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

388	**Case No.:167/6/82-ALC4/2020**	Party Name:TRANSPEK INDUSTRY LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01776/AM21/	RLA File :34/24/040/00196/AM21/	Lic.No/Date:3410046491 22.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

389	**Case No.:168/6/82-ALC4/2020**	Party Name:TRANSPEK INDUSTRY LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01777/AM21/	RLA File :34/24/040/00197/AM21/	Lic.No/Date:3410046492 22.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

390	**Case No.:169/6/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01778/AM21/	RLA File :03/94/040/00412/AM21/	Lic.No/Date:0310839084 23.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

391	**Case No.:170/6/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01779/AM21/	RLA File :03/94/040/00411/AM21/	Lic.No/Date:0310839085 23.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

392	**Case No.:171/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01780/AM21/	RLA File :09/24/040/00407/AM21/	Lic.No/Date:0910069374 23.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

393	**Case No.:172/6/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01781/AM21/	RLA File :09/24/040/00408/AM21/	Lic.No/Date:0910069377 23.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

394	**Case No.:173/6/82-ALC4/2020**	Party Name:MAKCUR LABORATORIES LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01782/AM21/	RLA File :08/24/040/00249/AM21/	Lic.No/Date:0810148893 26.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

395	**Case No.:174/6/82-ALC4/2020**	Party Name:ASHISH LIFE SCIENCE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01783/AM21/	RLA File :03/94/040/00571/AM21/	Lic.No/Date:0310839148 27.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

396	**Case No.:175/6/82-ALC4/2020**	Party Name:SHIRDI CHEMICALS PVT. LTD.	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01784/AM21/	RLA File :03/95/040/00469/AM21/	Lic.No/Date:0310839149 27.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

397	**Case No.:176/6/82-ALC4/2020**	Party Name:LACTOSE (INDIA) LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01785/AM21/	RLA File :03/95/040/00472/AM21/	Lic.No/Date:0310839161 27.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

398	**Case No.:177/6/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01786/AM21/	RLA File :09/24/040/00337/AM21/	Lic.No/Date:0910069393 27.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

399	**Case No.:178/6/82-ALC4/2020**	Party Name:R.L.FINE CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01787/AM21/	RLA File :07/24/040/00209/AM21/	Lic.No/Date:0710117187 27.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

400	**Case No.:179/6/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01788/AM21/	RLA File :03/94/040/00410/AM21/	Lic.No/Date:0310839173 28.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

401	**Case No.:180/6/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01789/AM21/	RLA File :03/94/040/00346/AM21/	Lic.No/Date:0310839184 28.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

402	**Case No.:181/6/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01790/AM21/	RLA File :03/94/040/00569/AM21/	Lic.No/Date:0310839187 28.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

403	**Case No.:182/6/82-ALC4/2020**	Party Name:ASHISH LIFE SCIENCE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01791/AM21/	RLA File :03/94/040/00570/AM21/	Lic.No/Date:0310839193 28.10.2020	
	Decision: This case appeared for the first time before Norms Committee. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

404	**Case No.:183/6/82-ALC4/2020**	Party Name:LACTOSE (INDIA) LTD.,	Meet No/Date:6/82-ALC4/2020 13.11.2020	**Status: Deferred**
	HQ File :01/82/050/01792/AM21/	RLA File :03/95/040/00462/AM21/	Lic.No/Date:0310839208 29.10.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

Meeting ended with thanks to Chair and participants

*****